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Abstract 
Sulfotransferases (SULTs) and UDP-glucuronosyltransferases (UGTs) are important 
detoxification enzymes and they contribute to the bioavailability and elimination of many 
drugs. They mainly catalyze sulfonation and glucuronidation of small lipophilic molecules 
that can be of endogenous or exogenous origin. Conjugation with a glucuronic acid or 
sulfonate moiety increases the water solubility of the substrates and their excretion 
through bile or urine. 
SULT1A3 is an extra-hepatic enzyme responsible for sulfonation of phenols and 
catechols. The most important endogenous substrate is dopamine, which is often used as a 
probe substrate for SULT1A3. A new method for analyzing dopamine-3-O-sulfate and 
dopamine-4-O-sulfate by high-performance liquid chromatography (HPLC) with 
electrochemical detection was developed and the enzyme kinetic parameters for their 
formation were determined using purified recombinant human SULT1A3. The apparent 
Km values for sulfonation at both hydroxyl groups were similar, but the maximal reaction 
rate was approximately six times higher for the formation of the 3-O-sulfate than the 4-O-
sulfate. The results show that SULT1A3 strongly favors the 3-hydroxy group of dopamine 
over the 4-hydroxy group, which indicates that it may be the major enzyme responsible for 
the difference between the circulating levels of dopamine sulfates in human blood. 
UGT1A10 is an important enzyme in the inactivation of drugs, among other 
compounds, and it is mainly expressed in the gastrointestinal tract. In this study, it 
emerged as the only UGT isoform capable of dopamine glucuronidation at a substantial 
level. All 19 known human UGTs were expressed as recombinant enzymes in baculovirus 
infected insect cells and their activity toward dopamine was screened using a sensitive 
liquid chromatography-tandem mass spectrometry method. Much lower or no dopamine 
glucuronidation activity was found for all other UGTs tested at 1 mM dopamine. The 
results obtained with recombinant enzymes were supported by studies with human 
intestinal and liver microsomes, because the affinities were similar for intestinal 
microsomes and UGT1A10. The affinity of dopamine to UGT1A10 was low and the KA 
value was 1000 times higher than the Km of SULT1A3, indicating that UGT1A10 is not an 
important enzyme in dopamine metabolism in vivo. Despite the low affinity, dopamine is a 
potential new probe substrate for UGT1A10 due to its selectivity. 
Dopamine was used to study the importance of phenylalanines 90 and 93 in 
UGT1A10. The results revealed distinct effects that are dependent on differences in the 
size of the side chain as much as on differences in their positions within the protein. 
Examination of twelve UGT1A10 mutants that had the phenylalanines replaced by six 
amino acids of different sizes revealed lower dopamine glucuronidation in all of them. 
Enzyme kinetic studies of four mutants, F90A, F90L, F93A, and F93L, showed that their 
substrate affinities were similar to that of UGT1A10, suggesting that F90 and F93 are not 
directly involved in dopamine binding in the active site. 
The glucuronidation of -estradiol and epiestradiol (-estradiol) was studied to 
elucidate how the orientation of the 17-OH group affects conjugation at the 3-OH or the 
17-OH of either diastereomer. The results show that, although many UGTs can catalyze 
estradiol glucuronidation, there are marked differences in their kinetics, regioselectivity, 
  
 
 
8
and stereoselectivity. The most active isoforms were UGT1A10 and UGT2B7, which 
demonstrated opposite regioselectivities. UGT1A10 favored the 3-OH of both estradiol 
diastereomers, as did UGT1A1, UGT1A3, UGT1A7, and UGT1A8. UGT2B7, like 
UGT2B4 and UGT2B17, favored the 17-OH. The stereoselectivities of UGT2B enzymes 
were more complex than those of UGT1As. UGT2B4 was specific for epiestradiol; 
UGT2B7 glucuronidated both diastereomers, with a high affinity for epiestradiol, whereas 
UGT2B17 only glucuronidated -estradiol. In accordance with the results with 
recombinant enzymes, the main products of human liver and intestinal microsomes were 
epiestradiol-17-glucuronide and -estradiol-3-glucuronide, respectively. 
The amino acid sequences of the human UGTs 1A9 and 1A10 are 93% identical, yet 
there are large differences in their activities and substrate selectivities. UGT1A9 
demonstrated much lower activity toward dopamine and estradiol than UGT1A10. 
However, inhibition studies revealed that -estradiol had similar affinities to UGT1A9 and 
UGT1A10. -Estradiol and epiestradiol, together with R- and S-propranolol and 
dobutamine, were used to further elucidate the differences in regio- and stereoselectivities 
of UGT1A9 and UGT1A10. Moreover, the kinetics of 1-naphthol glucuronidation was 
studied. To identify the residues responsible for the activity differences, several chimeras, 
in which segments of UGT1A9 were individually replaced by the corresponding segments 
from UGT1A10, were constructed and their activities were studied. In addition, the effects 
of various point mutations in UGT1A9 were studied. The results revealed that the residues 
between Leu86 and Tyr176 of UGT1A9 determine the substrate selectivity differences 
between UGT1A9 and UGT1A10. Within this region, residues at positions 115, 116, 117, 
152, and 169 had significant impacts on the catalytic properties that were studied here. It 
appears that Phe117 of UGT1A9 participates in 1-naphthol binding and the residues at 
positions 152 and 169 contribute to the higher glucuronidation rates of UGT1A10. 
In summary, the results emphasize that the substrate selectivity, including regio- and 
stereoselectivity, of UGTs is complex and it is controlled in subtle ways by many amino 
acids rather than one critical residue. Moreover, the results highlight the importance of the 
intestinal enzymes, SULT1A3 and UGT1A10, in the metabolism of dopamine and other 
physiological compounds as well as drugs and other xenobiotics. 
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Abbreviations 
ADME absorption, distribution, metabolism, and excretion 
cDNA complementary deoxyribonucleic acid 
Clint intrinsic clearance 
CYP cytochrome P-450 
DMSO dimethyl sulfoxide 
EC enzyme classification 
ER endoplasmic reticulum 
GI gastrointestinal 
GT-B glycosyltransferase protein topology where two domains are linked 
flexibly 
HEK293 a human embryonic kidney cell line 
His-tag polyhistidine tail 
HPLC high-performance liquid chromatography 
KA substrate concentration at 0.5 ×Vmax in Hill equation 
kcat turnover number 
Ki  dissociation constant of the inhibitory enzyme-substrate complex 
Km the Michaelis-Menten constant 
Ks the substrate concentration at 0.5 ×Vmax in the substrate inhibition equation 
mRNA messenger ribonucleic acid 
n the Hill coefficient 
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pNP p-nitrophenol 
PST phenolsulfotransferase 
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SULT sulfotransferase 
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UDP-GlcNAc uridine diphosphate N-acetylglucosamine 
UGT uridine diphosphoglucuronosyl transferase 
UGT a gene encoding UGT 
Vmax limiting rate of an enzymatic reaction, “maximum velocity” 
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Amino acids  3-Letter 1-Letter 
 
Alanine   Ala A  
Arginine   Arg R  
Asparagine   Asn N  
Aspartic acid   Asp D  
Cysteine   Cys C  
Glutamic acid   Glu E 
Glutamine   Gln Q 
Glycine   Gly G  
Histidine   His H  
Isoleucine   Ile I  
Leucine   Leu L 
Lysine   Lys K 
Methionine   Met M 
Phenylalanine   Phe F 
Proline   Pro P 
Serine   Ser S 
Threonine   Thr T  
Tryptophan   Trp W 
Tyrosine   Tyr Y 
Valine   Val V 
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1 Introduction 
The main goal of the drug development process is to produce safe and effective drugs 
within a reasonable time and for a reasonable cost. When a drug is administered to a 
patient, it is supposed to influence body functions, but that is not the only issue. The body 
also acts on the drug molecules, which affects both the safety and efficacy of the 
medication. First, the drug has to be absorbed. If the drug is taken orally, it usually goes 
from the intestine to the portal vein and liver before reaching the systemic circulation. 
Enzyme-catalyzed chemical transformation can occur in the intestine and liver during 
absorption, which is called first-pass metabolism. After reaching the systemic circulation, 
the drug is distributed to the tissues, including the target tissue, where it binds to its 
targets, e.g. receptors that mediate the drug’s action. After doing its job, the drug has to be 
excreted from the body through bile or urine, and most drugs undergo some metabolic 
modifications before that. The liver is the major metabolizing organ in the body, but 
metabolizing enzymes are also expressed in other tissues, such as the intestine, kidney, 
lung, and skin. With evolution, the human body has gained a huge variety of enzymes to 
take care of drug metabolism and to protect the body from harmful xenobiotics. In 
addition to drugs and other xenobiotics, many endogenous compounds go through 
metabolic reactions before excretion, and they compete for metabolizing enzymes. 
Drug metabolism can be divided into two phases that are catalyzed by different 
enzyme families. In phase I reactions, functional groups are added to or uncovered in the 
drug molecule. These reactions include oxidation, reduction, hydrolysis, hydration, and 
isomerization (Gibson and Skett, 2001). Cytochrome P450 (CYP) is the major enzyme 
family in phase I metabolism. In phase II reactions, the substrate molecules are conjugated 
to other molecules. Conjugation can occur on the drug molecule itself, or its metabolite 
from phase I reactions, and it usually renders the molecule much more hydrophilic and 
readily excreted, as well as less toxic. UDP-glucuronosyltransferases (UGT) and 
sulfotransferases (SULT) are the major phase II enzyme families. In addition to 
glucuronidation and sulfonation catalyzed by these enzymes, phase II reactions include 
glycosidation, methylation, acetylation, amino acid conjugation, glutathione conjugation, 
fatty acid conjugation, and condensation, all of which are catalyzed by a variety of 
different enzymes (Gibson and Skett, 2001).  
When a new compound is discovered and evaluated for use as a drug, its metabolism is 
studied at an early stage in order to avoid unwanted outcomes. For example, bio-
availability of a drug can be decreased if extensive first-pass metabolism prevents the 
molecule from getting to its target. In addition, some metabolites can be toxic or more 
active than the parent molecule. For example, morphine-6-O-glucuronide is an active 
metabolite of morphine (Lötsch and Geisslinger, 2001), minoxidil sulfate is the active 
form of minoxidil (McCall et al., 1983; Buhl et al., 1990), and many phase I metabolites 
(e.g. epoxides) as well as acyl glucuronides (Spahn-Langguth and Benet, 1992) may be 
toxic. Also, drug interactions may occur if two or more drugs are administered to a patient 
simultaneously or within a short period. If the drug molecules compete for the same 
metabolizing enzymes, or if one inhibits the function of a metabolizing enzyme, the 
concentration of the other can rise to a harmful level. Many chemicals can also induce the 
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expression of metabolizing enzymes, leading to more extensive metabolism and a lower 
blood concentration of the substrates. CYP-mediated interactions are quite common 
(Zhou, 2008), whereas clinical interactions mediated by UGT or SULT rarely occur, 
although many potential interactions have been found in vitro (Kiang et al., 2005). 
Metabolism also affects the elimination half-lives of most drugs. For example, if we think 
about a prescription drug that is taken daily for years, it becomes clear that the elimination 
half-life should be short enough so that the drug does not accumulate in the body. On the 
other hand, it should be long enough so that the drug can be administered only once a day. 
This increases compliance by the patient. If the elimination half-life is too short, the drug 
must be administered very frequently. Another important feature of drug metabolism is 
polymorphism of the metabolizing enzymes, which may cause unexpected variation in 
metabolism. Drug concentration in the blood can rise to a detrimental level if the patient 
carries a mutation in the metabolizing enzyme. For instance, catechol-O-methyltransferase 
inhibitors may cause hepatotoxicity in people carrying mutations in UGT1A9 (Martignoni 
et al., 2005). During the drug discovery and development process, the metabolism is 
normally studied from the CYP point of view, because most of the drugs that are currently 
in use are substrates of one or more CYPs. To avoid drug interactions, a new lead-
compound may be discarded, if it is a substrate or inhibitor of CYPs. This has slightly 
increased the importance of the phase II enzymes in drug development because the 
compounds that are accepted for the next round in the development process may still be 
substrates or inhibitors of UGTs, SULTs, and other conjugating enzymes. 
The increased ability to synthesize large numbers of potential drug candidates in a 
short time has made pharmacokinetic studies a bottleneck in the drug discovery process 
(Eddershaw and Dickins, 1999). There is a need for prediction tools that could be used in 
silico to assess potential problems in absorption, distribution, metabolism, or excretion 
(ADME) properties of a drug candidate in an early stage of the process. In order to be able 
to create predictive models for metabolism reactions, a lot of experimental data on the 
metabolizing enzymes and their structures and substrates must be generated. The lack of 
information on three-dimensional structures of the aglycone binding sites of UGTs has 
hindered the full understanding of the molecular basis of substrate recognition in these 
enzymes, and one way of getting more information about substrate recognition is to study 
their substrate specificities and the effects of site directed mutations on the proteins. For 
SULTs there are several crystal structures available (Kakuta et al., 1997; Bidwell et al., 
1999; Dajani et al., 1999b; Pedersen et al., 2000; Lee et al., 2003), which makes the case 
somewhat different. In this study, regio- and stereoselectivity of UGTs and SULT1A3 was 
examined using endogenous and exogenous substrates in concert with wild-type and 
mutated recombinant enzymes in order to get more detailed information on the molecular 
basis of their substrate recognition. 
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2 Review of the Literature 
The first two chapters of the literature review are focused on the enzyme families that 
were studied in this work, UDP-glucuronosyltransferases and sulfotransferases. This 
review covers the reaction types that are catalyzed by these two enzyme families, the gene 
localization, the nomenclature of the genes and enzymes, their expression in different 
tissues, and what is known about their structure and function to date. The third chapter of 
the review is focused on enzyme kinetics and the equations used in this study. 
2.1 UDP-glucuronosyltransferases (UGTs) 
2.1.1 Glucuronidation 
UDP-glucuronosyltransferases (EC 2.4.1.17; UGTs) are important conjugation enzymes 
that catalyze the glucuronidation of a large number of xenobiotic and physiological 
compounds. They are members of the UDP glycosyltransferase superfamily together with 
other enzymes that covalently attach glycosyl groups to other molecules. 
 
Figure 1. O-Glucuronidation catalyzed by UGTs. The catalytic base (B, histidine) in UGT 
accepts a proton from the aglycone substrate (phenol in this case). Negatively 
charged oxygen attacks the C1 atom of UDP-glucuronic acid (UDPGA). UDP is 
cleaved from UDPGA and it takes the extra proton from the enzyme (Yin et al., 
1994). 
In the glucuronidation reaction, the glucuronic acid moiety is transferred from UDP-
glucuronic acid (UDPGA) to an aglycone substrate (Fig. 1). Aglycone substrates are 
mainly small lipophilic molecules and conjugation with glucuronic acid increases their 
water solubility and their excretion through bile or urine (Tukey and Strassburg, 2000; 
King et al., 2000; Wells et al., 2004). Glucuronides are substrates for transport proteins 
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that facilitate their passage through cell membranes. Multidrug resistance-associated 
proteins 2, 3, and 4, as well as the breast cancer resistance protein play a major role in the 
hepatic excretion of glucuronides (reviewed by Zamek-Gliszczynski et al., 2006). 
Glucuronidation occurs as an SN2 reaction where the nucleophilic heteroatom of the 
aglycone attacks the C1 atom of glucuronic acid (Fig. 1; Yin et al., 1994; Johnson and 
Fenselau, 1978). In addition to the most common heteroatom, oxygen, the glucuronic acid 
moiety can also be attached to nitrogen, sulfur, or carbon atoms. The reaction follows a 
compulsory-order ternary-complex mechanism, which means that UDPGA and the 
aglycone always bind to the enzyme in the same order: UDPGA is bound first and the 
aglycone is bound after that (Luukkanen et al., 2005). The reaction occurs when both 
substrates are present in the active site as a ternary complex with the enzyme and both 
products, the glucuronide and UDP, are released subsequently. The reaction is reversible 
in principle but in an intact cell the reaction products are rapidly removed and hence the 
reverse reaction is not likely to occur (Bock and Köhle, 2009).  
2.1.2 UGT gene family 
UGTs are divided into two families, UGT1 and UGT2, based on their sequence similarity 
and chromosomal localization (Mackenzie et al., 2005; Fig. 2). The families are 
designated by a numeral following the abbreviation “UGT” and subfamilies are identified 
by letters. The isoforms are identified by numerals following the letter (e.g. UGT1A10). 
The UGT1 complex gene locus is located on chromosome 2 at position q37 and it 
encodes the nine functional members of the UGT1A subfamily, UGT1A1 and UGTs 1A3 
through 1A10 (Mackenzie et al., 2005; Gong et al., 2001). All these enzymes share exons 
2-5 and therefore the amino acid sequence of their C-terminal half is identical. The first 
exons are specific for the individual UGT1As and they encode the variable N-terminal 
domains of the proteins. However, there are also high levels of similarity among the N-
terminal domains of many UGT1As, particularly among UGTs 1A3-1A5 and UGTs 1A7-
1A10 (Guillemette, 2003).  
The human UGT2 genes are located on chromosome 4 at position q13 and they are 
divided into two subfamilies (Monaghan et al., 1994; Jedlitschky et al., 1999; Mackenzie 
et al., 2005). In the UGT2A subfamily there are three members, UGTs 2A1-2A3, and 
there is exon sharing between UGT2A1 and UGT2A2 that leads to identical C-terminal 
halves, as in the UGT1A subfamily (Sneitz et al., 2009). UGT2A3 and the UGT2Bs, on 
the other hand, are encoded by separate genes that contain all the exons (Mackenzie et al., 
2005). The human UGT2B subfamily contains at least 7 members: UGTs 2B4, 2B7, 2B10, 
2B11, 2B15, 2B17 and 2B28 (Turgeon et al., 2001; Levesque et al., 2001). In the UGT2B 
subfamily, a sequential numbering system, based on the chronological order of discovery 
of the genes, has been used, because orthologs across species are difficult to identify 
(Mackenzie et al., 1997; 2005).  
Recently, it was discovered that the diversity at the UGT1 gene locus is amplified by 
alternative splicing of exon 5 (Girard et al., 2007). This alternative splicing at the 3’ end 
leads to nine additional UGT1A proteins (UGT1A1_i2 and UGT1A3_i2-UGT1A10_i2) 
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that are not capable of glucuronidation. Subsequently, even more alternative exons were 
found for UGTs (Guillemette et al., 2010). Currently, the importance of this finding for 
glucuronidation in physiological conditions is not fully known, but it has been 
hypothesized that they may act as regulators of the glucuronidation activity of other 
UGTs. They also complicate the determination of the expression levels of active UGTs in 
tissues. 
Figure 2. A phylogenetic tree of the human UGTs showing percentage identity of the UGT 
families (Guillemette, 2003; Guillemette et al., 2010). 
2.1.3 Diverse expression of UGTs 
The UGTs are expressed mainly in the liver but also in many other tissues, such as the 
gastrointestinal tract and respiratory organs, both of which are important routes of drug 
administration (Table 1). The expression of UGT genes is regulated by many transcription 
factors like the hepatocyte nuclear factor 1, octamer transcription factor 1, and caudal 
related homeodomain protein (Mackenzie et al., 2003; Gregory et al., 2004). In addition, 
many hormones and xenobiotic chemicals such as dihydrotestosterone, rifampicin, and 
phenobarbital can induce expression through nuclear receptors such as the pregnane X 
receptor and constitutive androstane receptor (Mackenzie et al., 2003; Zhou et al., 2005), 
which can cause interindividual variation in the metabolism of drugs that are substrates for 
UGTs.  
 
UGT1A10
UGT1A7
UGT1A8
UGT1A9
UGT1A6
UGT1A5
UGT2A1
UGT2A2
UGT2B4
UGT2B15
UGT2B17
UGT2B7
UGT2B11
UGT2B28
UGT2B10
UGT2A3
41%
66%
UGT1A4
UGT1A3
UGT1A1
59%
UGT2
UGT1
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Table 1. Tissue-specific mRNA expression of UDP-glucuronosyltransferases. 
UGT  Tissues References 
1A1 
Liver 
Hepatic and biliary tissue 
Gastric tissue  
Colon 
Liver, small intestine, kidney, colon, trachea 
Liver and GI tract 
Ritter et al., 1991 
Strassburg et al., 1997 
Strassburg et al., 1998a 
Strassburg et al., 1998b 
Nishimura and Naito, 2006 
Ohno and Nakajin, 2009 
1A3 
Liver and colon 
Hepatic, gastric and biliary tissue 
Liver, kidney, colon, prostate, small intestine 
Liver and small intestine 
Mojarrabi et al., 1996 
Strassburg et al., 1997 
Mojarrabi and Mackenzie, 1998 
Ohno and Nakajin, 2009 
1A4 
Liver 
Hepatic and biliary tissue 
Colon 
Ritter et al., 1991; Ohno and Nakajin, 2009 
Strassburg et al., 1997 
Strassburg et al., 1998a 
1A5 Low mRNA in liver and GI tract GI tract, kidney, esophagus 
Finel et al., 2005 
Ohno and Nakajin, 2009 
1A6 
Liver 
Hepatic, gastric and biliary tissue 
Colon 
Liver, kidney and brain (cerebellum) 
Larynx  
Liver, kidney, stomach, trachea, small intestine, 
adrenal, but not in brain 
Harding et al., 1988  
Strassburg et al., 1997 
Strassburg et al., 1998a  
King et al., 1999 
Zheng et al., 2002 
Nishimura and Naito, 2006; Ohno and 
Nakajin, 2009 
1A7 
Gastric tissue 
Esophagus 
Aerodigestive tract* 
Esophagus, trachea, cervix, kidney, GI tract 
Strassburg et al., 1997 
Strassburg et al., 1999 
Zheng et al., 2002 
Ohno and Nakajin, 2009 
1A8 
Small intestine, colon 
Colon 
 
Esophagus 
Larynx 
Hepatocytes 
Colon, small intestine, adrenal 
Cheng et al., 1998  
Strassburg et al., 1998a;  
Mojarrabi and Mackenzie, 1998   
Strassburg et al., 1999  
Zheng et al., 2002  
Li et al., 2007b 
Ohno and Nakajin, 2009 
1A9 
Liver 
Colon 
Esophagus 
Kidney, liver (low mRNA in adrenal, colon, small 
intestine, stomach and trachea)  
Wooster et al., 1991 
Strassburg et al., 1998a 
Strassburg et al., 1999 
Nishimura and Naito, 2006; Ohno and 
Nakajin, 2009 
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Table 1.   Continued. 
 
UGT  Tissues References 
1A10 
Biliary and gastric tissue 
Colon 
Colon and small intestine 
 
Esophagus 
Aerodigestive tract* 
Hepatocytes 
Breast 
GI tract, esophagus, trachea, adrenal 
Strassburg et al., 1997 
Strassburg et al., 1998a 
Mojarrabi and Mackenzie, 
1998; Cheng et al., 1999 
Strassburg et al., 1999 
Zheng et al., 2002 
Li et al., 2007b 
Starlard-Davenport et al., 2008 
Ohno and Nakajin, 2009 
2A1 
Olfactory tissue and brain 
Low mRNA in trachea and lung 
Jedlitschky et al., 1999 
Nishimura and Naito, 2006 
2A2 Nasal mucosa Sneitz et al., 2009 
2A3 Small intestine, liver, colon and adipose tissue (low in pancreas, kidney, stomach, and testis) 
Court et al., 2008 
2B4 
Liver, kidney, testis, mammary gland, placenta,  
adipose tissue, skin, prostate, adrenal, lung, heart, 
trachea, esophagus, thymus 
Tongue and floor of mouth 
Levesque et al., 1999; Ohno and 
Nakajin, 2009 
 
Zheng et al., 2002 
2B7 
Liver, kidney, pancreas and brain (cerebellum) 
Esophagus, liver 
Liver, kidney, mammary gland and intestine 
Liver, small intestine 
Kidney, liver, colon, small intestine  
King et al., 1999 
Strassburg et al., 1999 
Turgeon et al., 2001 
Nishimura and Naito, 2006 
Ohno and Nakajin, 2009 
2B10 
Esophagus, liver 
Liver, kidney, mammary gland, intestine, lung,  
spleen  
Liver 
Strassburg et al., 1999 
Turgeon et al., 2001 
 
Nishimura and Naito, 2006; 
Ohno and Nakajin, 2009 
2B11 
Mammary gland, adipose, skin, lung, adrenal,  
liver, kidney, prostate 
Beaulieu et al., 1998 
2B15 
Liver, prostate, testes 
Liver (low mRNA in stomach and pancreas) 
Liver, GI tract, breast, prostate, trachea, testes 
Chen et al., 1993 
Nishimura and Naito, 2006 
Ohno and Nakajin, 2009 
2B17 
Liver, testes, mammary gland, lung (low in  
prostate, uterus, kidney) 
Tonsil and larynx  
GI tract, liver (low mRNA in various other tissues) 
Beaulieu et al., 1996 
 
Zheng et al., 2002 
Nishimura and Naito, 2006; 
Ohno and Nakajin, 2009 
2B28 Liver and mammary gland 
Bladder 
Levesque et al., 2001 
Nakamura et al., 2008 
*Aerodigestive tract tissues include tongue, tonsil, larynx, esophagus, and floor of mouth. 
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 In addition to enzyme inducers (e.g. medication, smoking, alcohol), interindividual 
variation in drug metabolism is caused by genetic polymorphism (meaning the differences 
in DNA sequence among individuals). Polymorphisms have been described for almost all 
human UGTs [for a comprehensive list, see the UGT allele nomenclature homepage 
www.ugtalleles.ulaval.ca (accessed 9.7.2010)]. Some are single nucleotide polymorphisms 
(SNP) that do not result in an amino acid change in a polypeptide (i.e. silent mutation). In 
contrast, many types of mutations also lead to changes in the amino acid sequence. 
Missense mutations lead to amino acid changes in the protein, and nonsense mutations add 
a stop codon to the mRNA, leading to pre-mature truncation of the protein. Insertion and 
deletion (indel) mutations insert or delete nucleotides in the DNA sequence, leading to 
frameshifts and non-functional proteins. Deletion or amplification of a longer fragment of 
DNA causes copynumber variation. In addition, mutations in promoter regions and in 
splice acceptor or donor sites of the introns have been reported and they are listed on the 
UGT allele nomenclature homepage.  
UGT1A10 is an important enzyme in the inactivation of dietary carcinogens (Dellinger 
et al., 2007) and it is mainly expressed in the gastrointestinal tract (Table 1). To date, six 
polymorphic amino acid changes in the N-terminal domain have been detected: M59I, 
T202I (Saeki et al., 2002), E139K, T240M, L244I (Elahi et al., 2003), and I211T 
(Martineau et al., 2004). The polymorphism where Glu139 is replaced by lysine lowers 
the glucuronidation activity of UGT1A10 toward carcinogenic polycyclic aromatic 
compounds (Dellinger et al., 2006; 2007). The polymorphic variant T202I has lower 
glucuronidation activity toward estradiol than the wild-type UGT1A10 (Jinno et al., 
2003), whereas mutation I211T abolishes all activity (Martineau et al., 2004). However, 
not all missense mutations affect the enzymatic activity. The activity of the variant M59I, 
for example, is similar to that of the wild-type UGT1A10 (Jinno et al., 2003). 
Copynumber variation has been found in the UGT2B17 gene (Murata et al., 2003; 
Wilson III et al., 2004). It has been noticed previously that the mRNA levels of UGT2B17 
can vary more than 100 fold between individuals (Congiu et al., 2002). Because 
UGT2B17 is an important enzyme in testosterone glucuronidation, this leads to significant 
interindividual differences in the metabolism of this endogenous androgen (Jakobsson et 
al., 2006).  
Polymorphisms in the UGT1A1 gene are clinically the most important, because 
UGT1A1 is the only enzyme that significantly catalyses bilirubin glucuronidation in man 
(Bosma et al., 1994). A complete lack of UGT1A1 activity results in Crigler–Najjar 
syndrome type I, where the concentration of the neurotoxic bilirubin can rise to a fatal 
level if the patient is left untreated (Crigler and Najjar, 1952; Ritter et al., 1991; Bosma et 
al., 1994). There are at least 113 different alleles of UGT1A1 [www.ugtalleles.ulaval.ca 
(accessed 9.7.2010)]. Loss of activity can be due to mutations in the promoter region or 
any exon or intron. Milder UGT1A1 deficiency leads to Crigler–Najjar syndrome type II 
and Gilbert’s syndrome, which cause jaundice but are often harmless.  
Neonatal jaundice is also very common in normal healthy babies. One of the reasons is 
that the UGT activity in general is lower in newborns than in adults (Strassburg et al., 
2002), which also affects their drug metabolism. This should be taken into account when 
prescribing medications to newborns. On the other hand, old age seems to have only a 
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minor impact on glucuronidation activity in human liver and the same holds true for sex 
differences (Court, 2010).  
2.1.4 Structure and substrate selectivity of UGTs 
The UGTs are membrane proteins that are located mostly in the endoplasmic reticulum 
(ER) and to a lesser degree in Golgi membranes and nuclear envelope, but not in the 
cytosol (Hauser et al., 1984; Radominska-Pandya et al., 2002; Dellinger et al., 2007). 
They demonstrate type I topology, meaning that the C-terminus is located on the 
cytoplasmic side of the membrane and N-terminus on the lumenal side. They form 
functional homo- and heterodimers or even higher oligomers in membranes (Fig. 3; 
Meech and Mackenzie, 1997; Ghosh et al., 2001; Kurkela et al., 2003; 2004; 2007; 
Fujiwara et al., 2007; Operana and Tukey, 2007; Finel and Kurkela, 2008).  
 
Figure 3. A schematic model for the membrane topology of human UGTs (Finel and Kurkela, 
2008). 
UGTs adopt a GT-B fold, which means that one monomer is mainly composed of two 
large domains, N-terminal and C-terminal, and the domains are connected by a flexible 
linker (Lairson et al., 2008). There is a cytoplasmic tail of 20-25 residues in the C-terminal 
half and a 17-residue helix that spans the ER membrane. The rest of the protein is located 
in the lumen of the ER but there is most likely an additional membrane-binding 
hydrophobic region within the N-terminal domain (Ouzzine et al., 1999). The active site is 
on the lumenal side of the membrane (Shepherd et al., 1989), which means that the 
aglycone substrates and UDPGA must pass through the ER membrane in order to reach 
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the active site, and the glucuronides must be transported out from the lumen in order to be 
excreted from the cell and finally from the body. The aglycone substrates are usually 
hydrophobic small molecules, thus they may pass through the membranes passively. 
However, their access to the active site may be facilitated by the N-terminal membrane-
bound domain (Ouzzine et al., 1999). For UDPGA and glucuronides there are probably 
active transport mechanisms in the ER membrane (Bossuyt and Blanckaert, 1994; 
Muraoka et al., 2001; Battaglia and Gollan, 2001; Csala et al., 2004).  
UGTs are difficult to purify and crystallize and hence no X-ray crystal structure of a 
whole UGT is available to date. Miley et al. (2007) were able to resolve the crystal 
structure of the C-terminal UDPGA binding domain of UGT2B7, which is the first crystal 
structure of any region of a mammalian UGT. At the core of this domain, there is a six-
stranded -sheet surrounded by seven -helices (Miley et al., 2007). The UDPGA binding 
pocket is a shallow cavity on the surface of the domain. In a native protein, the N-terminal 
domain sits on top of this cavity, forming a catalytic cleft between the domains. The 
aglycone binding site is located in the N-terminal domain (Mackenzie, 1990; Lewis et al., 
2007; Patana et al., 2008).  
In the absence of detailed structural data on the aglycone binding site, other 
approaches have been used in attempts to determine the amino acids that are essential for 
the substrate specificity and catalytic activity of the enzymes. These approaches include 
enzyme kinetic studies, structure-activity studies, construction of pharmacophore models, 
molecular modeling, use of amino acid-modifying reagents, and site-directed mutagenesis 
of individual UGTs (Dubois et al., 1999; Smith et al., 2003a; 2003b; Barre et al., 2007; 
Kubota et al., 2007; Lewis et al., 2007; Nishiyama et al., 2008; Sorich et al., 2008; 
Laakkonen and Finel, 2010). Along with these methods, considerable in vitro 
glucuronidation data with diverse chemicals have been generated so far, but more data are 
still needed for better understanding of UGT structure and function. The amino acids that 
have been found to be important for the substrate selectivity or enzymatic activity of 
UGTs are given in Table 2. A recent review on this topic was written by Magdalou et al. 
(2010).  
In the C-terminal domain, many amino acids have been identified that are involved in 
the binding of UDPGA. Consistent with the fact that, in the glucuronidation reaction, the 
bond between glucuronic acid and the phosphate group is broken, the amino acid residues 
closer to the glucuronic acid and phosphate group of UDPGA are more critical for the 
enzymatic function than those closer to the other end of the UDPGA binding site (Miley et 
al., 2007; Patana et al., 2007). 
In the N-terminal domain, two amino acids have been identified as catalytic residues in 
UGTs (Table 2). A His residue is found at position 35-40 in all other UGTs except 
UGT1A4 and UGT2B10, and it functions as a catalytic base in O-glucuronidation (Kubota 
et al., 2007; Li et al., 2007a; Miley et al., 2007; Patana et al., 2008). An Asp at position 
150 or 151 is the catalytic acid that stabilizes the protonated His during catalysis (Li et al., 
2007a; Miley et al., 2007). 
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Table 2. Some amino acids found to be important for enzymatic activity and substrate 
selectivity of UGTs. The amino acid residues are numbered according to the 
original publications. 
Amino acids (UGT) Functions References 
N-terminal domain   
His40/Pro40 (1A3/1A4) 
His35 (2B7) 
His37 (1A9) 
Catalytic His is critical in O- 
glucuronidation  but not in N- 
glucuronidation  
Miley et al., 2007; Kubota et 
al., 2007; Li et al., 2007a;  
Patana et al., 2008 
Asp150 (1A6) 
Asp151 (2B7) 
Catalytic Li et al., 2007a 
Miley et al., 2007 
Aromatic residue at 
position 33 (2B4 and 2B7) 
Important for substrate 
specificity and activity 
Barre et al., 2007 
Arg52 and His54 (1A6) Required for optimal function 
and structural integrity 
Senay et al., 1997 
Phe90 and Phe93 (1A10) Substrate binding Xiong et al., 2006; Starlard-
Davenport et al., 2007 
Ser121 (2B17) Required for activity toward 
the 3-position of C19 steroids 
Dubois et al., 1999 
Cys126 (1A6) Maintaining the integrity of 
the substrate binding site 
Senay et al., 2002 
Residues 61-194 (2B7 and 
2B15) 
Substrate binding and 
selectivity 
Lewis et al., 2007  
Residues 69-132 (1A9) Important in C-glucuroni- 
dation of phenylbutazone 
Nishiyama et al., 2008 
Residues 96-101 (2B7) Binding of opioids Coffman et al., 2003  
Cys186 (1A1) Affinity for bilirubin Ghosh et al., 2005 
Cys127, Cys156, Cys177, 
Cys223, Cys280 (1A1) 
Mutations abolish activity Ghosh et al., 2005 
Ile211 (1A10) Essential for activity Martineau et al., 2004 
C-terminal domain   
Residues 308, 338, 356, 
359, and 382 (2B7) 
Interact with the nucleotide 
end of the UDPGA 
Miley et al., 2007 
His371 and Glu379 (1A6) Binding of UDPGA Patana et al., 2007 
Residues 373, 374, 378, 
and 379 (2B7) 
Interact with phosphate Miley et al., 2007 
Residues 378, 398, and 399 
(2B7) 
Interact with the glucuronic 
acid moiety of UDPGA 
Miley et al., 2007 
Cys383 (1A1) Mutations abolish activity Ghosh et al., 2005 
Asp393 (1A10) Binding of UDPGA Xiong et al., 2008 
Lys314 and Lys404 (1A10) Binding of UDPGA Banerjee et al., 2008 
Cytoplasmic tail   
Cys509, Cys510, Cys517 
(1A1) 
Stimulation of the enzyme 
activity by UDP-GlcNAc 
Ghosh et al., 2005 
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Table 3. Typical substrates of UGTs. 
Additionally, in the N-terminal domain, some other amino acids have been found to be 
important for glucuronidation activity. In the absence of a three-dimensional structure of 
the N-terminal domain, it is not always easy to tell whether they participate in substrate 
binding. Many of the crucial amino acids may, on the other hand, be important for the 
UGT  Characteristic substrates References 
1A1 Bilirubin Bosma et al., 1994; Senafi et al., 1994 
1A3 Small phenolic compounds, 
scopoletin, carboxylic acid drugs 
Green et al., 1998; Vashishtha et al., 2000 
1A4 Tertiary amines, imidazoles Green et al., 1995; Vashishtha et al., 2001 
1A5 1-Hydroxypyrene Finel et al., 2005 
1A6 Small planar phenols, 
serotonin 
King et al., 1999; Ebner and Burchell, 1993; 
Krishnaswamy et al., 2003 
1A7 Phenolic compounds Strassburg et al., 1998a 
1A8 
Steroids, fatty acids, bile acids,  
flavonoids, anthraquinones, and  
other phenolic compounds 
Mojarrabi and Mackenzie, 1998; Cheng et  
al., 1999 
1A9 Bulky phenols, propofol,  
entacapone 
Ebner and Burchell, 1993 
Lautala et al., 2000 
1A10 
Steroids and other phenolic 
compounds; 
Polycyclic aromatic hydrocarbons 
Strassburg et al., 1998a; Mojarrabi and  
Mackenzie, 1998; Cheng et al., 1999 
Dellinger et al., 2006 
2A1 Phenolic compounds Jedlitschky et al., 1999; Sneitz et al., 2009 
2A2 Hyodeoxycholic acid,  3- and 4-phenylphenol 
Sneitz et al., 2009 
2A3 Hyodeoxycholic acid and other bile acids 
Court et al., 2008 
2B4 Hyodeoxycholic acid, 
catechol estrogens, phenols 
Levesque et al., 1999; Fournel-Gigleux et  
al., 1991; Jin et al., 1993 
2B7 NSAIDs, steroids, bile acids, 
opioids 
Jin et al., 1993; Jin et al., 1997; Coffman et  
al., 1997; 1998; Gall et al., 1999 
2B10 Nicotine,  medetomidine Kaivosaari et al., 2007; 2008 
2B11 Not known Beaulieu et al., 1998 
2B15 5-Androstane 3, 17-diol and 
other steroids and phenols 
Chen et al., 1993; Green et al., 1994 
2B17 Dihydrotestosterone and other  
steroids and phenols 
Beaulieu et al., 1996 
2B28 5-Androstane 3,17-diol and 
other steroids and phenols 
Levesque et al., 2001 
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integrity of the protein structure. Differences in substrate selectivity among the UGTs are 
mainly due to the variable region within the N-terminal domain, roughly residues 60-200. 
Substrate selectivity of UGTs is very complex since most of them can glucuronidate 
several different compounds that vary significantly in their chemical structure. There is 
often a partial overlap in the substrate specificity of human UGTs, reflecting the high 
sequence homology among them. On the other hand, there are some distinct differences in 
activity even between highly similar isoforms such as UGTs 1A3 and 1A4 (Kubota et al., 
2007), 1A9 and 1A10 (Sten et al., 2006), and 2B15 and 2B17 (Dubois et al., 1999).  Some 
typical substrates of UGTs are summarized in Table 3. Some of them are more selective 
than others. Due to the lack of absolutely specific substrates or inhibitors for most UGTs, 
substrate selectivity is usually studied with individually expressed recombinant enzymes. 
One of the major challenges in current UGT research is to better understand the factors 
that determine the substrate specificity of UGTs in order to be able to predict the 
glucuronidation of new compounds. There is a clear need for additional detailed 
information on the preferences of these enzymes with respect to different substrates and 
regio- and stereoselective conjugation. 
2.1.5 Substrate selectivity of UGT1A10 
Although all the human UGTs were included in this work, the substrate selectivity of 
UGT1A10 deserved extra attention during the course of these studies. UGT1A10 belongs 
to the UGT1A subfamily where the percent identity among the isoforms in general is 66% 
or more (Fig. 2). UGTs 1A7, 1A8, 1A9, and 1A10 form a subgroup within the UGT1A 
subfamily since they are more than 80% identical in amino acid sequence. There are only 
16 unique amino acid residues in mature UGT1A10 that are not identical to those from 
UGT1A7, 1A8, or 1A9: E67, N87, A102, Q103, S114, L117, T152, T169, H176, N192, 
D193, W208, V212, D216, L223, and R225 (Fig. 4). Yet it has somewhat different 
substrate selectivity from the other three (Kuuranne et al., 2003; Alonen et al., 2005; Sten 
et al., 2006). Some of the differences will be further discussed under Results and 
Discussion. 
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Figure 4. Sequence alignment of the amino acid sequences encoded by the first exons of UGT 
1A7, 1A8, 1A9, and 1A10. The signal sequence, which is marked with a dashed line, 
is cleaved from the protein after transport to the endoplasmic reticulum. 
2.2 Sulfotransferases (SULTs) 
2.2.1 Sulfonation 
Sulfotransferases (EC 2.8.2., SULTs) are generally considered to be cytosolic conjugation 
enzymes, but at least one of them (SULT2B1_v2) has also been found in the nucleus (He 
et al., 2004; Dumas et al., 2008). SULTs catalyze the transfer of a sulfonate group (-SO3-) 
from the donor substrate 3’-phosphoadenosine 5’-phosphosulfate (PAPS) to acceptor 
substrates that can be either xenobiotic or small endogenous compounds (reviews: Falany, 
1997; Coughtrie, 1998; 2002; Glatt et al., 2001; Allali-Hassani et al., 2007). The most 
common acceptor groups are aromatic or aliphatic hydroxyls whose conjugation results in 
a sulfate (R-OSO3-) moiety (Fig. 5). A widely used term for this reaction, sulfation, was 
derived from early studies that identified phenolic sulfate esters in the urine of humans 
treated with phenols. However, it would be more appropriate to use the term sulfonation, 
because it is a sulfonate group that is actually transferred in the reaction. SULTs are also 
capable of conjugating sulfonate to groups other than hydroxyls, including primary 
amines, whose conjugation does not result in a sulfate but in a sulfamate group. 
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Sulfonation greatly increases the water-solubility of the acceptor substrate since the 
resulting group is negatively charged in the physiological pH range.  
The mechanism of cytosolic sulfotransferases is a sequential Bi Bi kinetic mechanism 
that proceeds via a ternary complex between the enzyme and the two substrates, PAPS and 
the acceptor substrate (Duffel and Jakoby, 1981; Varin and Ibrahim, 1992; Zhang et al., 
1998). Both random ordered (Zhang et al., 1998) and compulsory ordered (Whittemore et 
al., 1985; Tyapochkin et al., 2008) binding of substrates have been suggested. Sulfonation 
occurs as a dissociative substitution with a loose transition state and little nucleophilic 
involvement (Kakuta et al., 1998; Bartolotti et al., 1999; Hoff et al., 2006). SULTs can 
also catalyze the reverse reaction, namely the transfer of the sulfonate moiety from a 
phenol substrate to PAP and other nucleotides (Duffel and Jakoby, 1981; Lin and Yang, 
2000). Sulfonate group transfer between two phenols and PAP-independent hydrolysis of 
phenyl sulfate has also been demonstrated in vitro (Duffel and Jakoby, 1981). Divalent 
cations activate some sulfotransferases, although they are not necessarily required for the 
catalysis, unlike many other enzymatic transfer reactions that involve nucleotides (Zhang 
et al., 1998). 
 
Figure 5. Sulfonation of a phenolic compound catalyzed by SULT. 
SULTs are often referred to as “high affinity and low capacity enzymes” meaning that 
they are most effective at low substrate concentrations. They have a fast initial turnover 
rate, but the reaction velocity decreases as the concentration of available cofactor is 
rapidly depleted. The concentration of PAPS in the liver and other tissues is much lower 
than that of UDPGA, for example (Cappiello et al., 1989; Cappiello et al., 1991). The 
reason for this might be that the synthesis of PAPS requires two molecules of ATP, thus it 
consumes a lot of energy in the cell. Another important factor is the availability of 
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inorganic sulfate. In vivo, the sulfonation pathway is additionally affected by sulfatases 
and transport proteins that hydrolyze sulfates or pump them out of the cell, respectively 
(reviewed by Coughtrie et al., 1998). 
Although sulfonation is usually considered to be a detoxicating process for 
endogenous and xenobiotic compounds, it actually activates some drugs and promutagens 
(Buhl et al., 1990; Garay et al., 1990; Garay et al., 1995). Many promutagens that are 
activated by sulfonation form covalent bonds to DNA and other macromolecules (Glatt, 
1997). Most SULTs are expressed in the intestine (see below) and it has been suggested 
that sulfonation may have an impact on the initiation of intestinal cancer (Coughtrie et al., 
1998). A vegetable-rich diet may be useful in preventing such cancer because many 
SULTs are inhibited by the flavonoids and isoflavonoids that are found in fruits and 
vegetables (Harris and Waring, 2008). 
2.2.2 SULT nomenclature 
Blanchard et al. proposed nomenclature guidelines for cytosolic SULTs in 2004 
(Blanchard et al., 2004). Prior to that, naming of the sulfotransferases was very confusing 
as many research groups had their own names for them and sometimes it was difficult to 
know if they were speaking about the same isoform or not. The proposed system is 
parallel to the UGT nomenclature system: SULTs sharing at least 45% amino acid 
sequence identity are considered members of the same family and those sharing at least 
60% identity are members of the same subfamily. 
There are at least 12 human SULT isoforms divided into four families that are further 
divided into 8 subfamilies altogether (Coughtrie, 2002). In the SULT1 family there are at 
least 7 enzymes functionally expressed in humans belonging to four subfamilies: 
SULT1A, SULT1B, SULT1C and SULT1E (Blanchard et al., 2004). Enzymes previously 
called SULT1C1 and SULT1C2 were re-named SULT1C2 and SULT1C4, respectively, in 
the proposed nomenclature system (Blanchard et al., 2004), and this may cause some 
confusion as some scientists have not adopted the new names. In the SULT2 family, there 
are three isoforms belonging to two subfamilies: SULT2A1, SULT2B1_v1 and 
SULT2B1_v2. In the SULT4 family, there is only one member: SULT4A1. The newest 
finding is SULT6B1, which is expressed at least in human testes, as well as in other 
primates (Freimuth et al., 2004), but there is very little data available about this isoform to 
date and it will not be discussed further in this review.  
2.2.3 Tissue specific expression of SULTs 
Like UGTs, many SULTs are highly expressed in the liver but also (and some exclusively) 
in other tissues like intestine, brain, endometrium, and kidney (Table 4). In liver, 
SULT1A1 is the most abundant isoform followed by SULT2A1 (Fig. 6; Riches et al., 
2009). In the small intestine, SULT1B1 and SULT1A3 are the most abundant forms and 
the total SULT content is higher than in the liver. Interindividual variation in both tissues 
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is very high. Some SULTs are expressed in different tissues in the fetus than in the adult: 
e.g. SULT1A3 has been found in fetal liver but not in adult liver (Richard et al., 2001). 
The physiological implications of this are currently unknown. 
 
Table 4. Tissue-specific protein expression of human sulfotransferases. 
SULT Tissue References 
1A1 
Liver, adrenal gland, placenta, platelets 
Endometrium 
Liver, gastrointestinal (GI) tract, brain,  
prostate, adrenal, bladder, cervix, uterus,  
ovary, skin, esophagus, and pancreas 
Heroux et al., 1989  
Falany et al., 1998  
Nowell et al., 2005  
 
1A2 Not detected at the protein level Liver and cecum 
Nowell et al., 2005 
Teubner et al., 2007 
1A3 
Brain 
Platelets 
Jejunal mucosa 
Placenta, platelets 
Fetal liver 
Whittemore et al., 1985 
Heroux and Roth, 1988 
Sundaram et al., 1989 
Heroux et al., 1989 
Richard et al., 2001 
1B1 Liver, small intestine, colon, blood  leukocytes 
Wang et al., 1998 
1C2 Stomach, kidney, thyroid, fetal kidney, and  fetal liver (mRNA) 
Her et al., 1997  
1C4 Fetal kidney, fetal lung (mRNA) Sakakibara et al., 1998b 
1E1 
Liver 
Liver, small intestine, adrenal gland, fetal 
lung, fetal liver, and fetal kidney 
Endometrium 
Forbes-Bamforth and Coughtrie, 1994 
Her et al., 1996  
 
Falany et al., 1998 
2A1 Liver and adrenal Liver and small intestine 
Comer and Falany, 1992  
Her et al., 1996  
2B1 
Prostate, placenta, and trachea (mRNA) 
Skin (2B1_v2) 
Breast (2B1_v2) 
Her et al., 1998  
Higashi et al., 2004  
Dumas et al., 2008 
4A1 Brain (mRNA) Cerebral cortex, cerebellum, and brainstem 
Falany et al., 2000  
Liyou et al., 2003 
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Figure 6. Relative expression levels of five major sulfotransferases in liver and small intestine 
(Riches et al., 2009). 
2.2.4 Chromosomal localization and polymorphism of SULTs 
SULT genes are located on various chromosomes. SULT1A genes are located on the short 
arm of chromosome 16 at 16p11.2-12.1 and they have probably evolved from a common 
ancient gene by duplication (Dooley et al., 1994; Dooley and Huang, 1996). Two genes, 
SULT1A3 and SULT1A4, encode the same enzyme, SULT1A3 (Hildebrandt et al., 2004). 
SULT1B1 and SULT1E1 are located on the chromosome 4 (as the UGT2 genes) at 4q13.1 
(Glatt et al., 2001; Her et al., 1995), whereas SULT1C genes are located on chromosome 2 
at 2q11.1-11.2 (Freimuth et al., 2000). SULT2 genes are located on chromosome 19 at 
19q13.3 (Freimuth et al., 2004; Her et al., 1998), where SULT2B1 gene encodes two 
protein products, SULT2B1_v1 and SULT2B1_v2, that have different first exons (Her et 
al., 1998), like the products of the UGT1 gene locus (see 2.1.2). SULT4A1 is located alone 
on the long arm of chromosome 22 at 22q13, which suggests that it has developed 
individually without undergoing duplication (Freimuth et al., 2004; Minchin et al., 2008 
and refs. therein). 
Genetic polymorphisms have been found for many isoforms. At least SULT1A1 
(Raftogianis et al., 1997), SULT1A2 (Raftogianis et al., 1999), SULT1A3 (Thomae et al., 
2003), SULT1C2 (Freimuth et al., 2001), SULT1E1 (Adjei et al., 2003), and SULT2A1 
(Thomae et al., 2002) are polymorphic. The physiological and pathological significance of 
these polymorphisms is still unclear, but it seems that there is a relationship between 
SULT1A1 polymorphism and various cancers (reviewed by Hildebrandt et al., 2009). 
2.2.5 Structure and substrate selectivity of SULTs 
SULTs are soluble proteins, which makes them easier to purify and crystallize than the 
UGTs. There are therefore many crystal structures available for SULTs. The X-ray crystal 
structure of mouse estrogen sulfotransferase SULT1E1 was the first to be solved (Kakuta 
et al., 1997). The first structural determination of human SULT was done for SULT1A3 
Small Intestine
SULT1A1
19 %
SULT1E1
8 %
SULT1B1
36 % SULT1A331 %
SULT2A1
6 %
Liver
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(Bidwell et al., 1999; Dajani et al., 1999b; Lu et al., 2005) followed by SULT2A1 
(Pedersen et al., 2000), SULT1E1 (Pedersen et al., 2002), SULT1A1 (Gamage et al., 
2003), SULT1B1 and SULT1C2 (Dombrovski et al., 2006), and most recently SULT1C4 
and SULT4A1 (Allali-Hassani et al., 2007). The overall structure consists of a five-
stranded -sheet and surrounding -helices. A comprehensive review of the structure and 
function of SULTs has been done by Negishi et al. (2001). 
The crystal structures and amino acid sequences reveal many conserved motifs in 
SULTs. One of them is the peptide sequence RKGxxGDWKNxFT in the C-terminal 
domain that is thought to take part in PAPS binding (Komatsu et al., 1994). In the mouse 
SULT1E1 structure, residues 257-259 (Arg, Lys, and Gly, corresponding to the first three 
residues in the conserved motif) together with Arg130 and Ser138 are involved in 
3’phosphate binding, and residues 48-51 (Lys, Ser, Gly and Thr) are involved in 
5’phosphate binding of PAP (Kakuta et al., 1997). The recognition of PAP was found to 
be similar in human SULT1A3 (Dajani et al., 1999b). When PAPS is bound in the active 
site of human SULT1E1, the conformation of Lys47, corresponding to Lys48 in the mouse 
SULT1E1 structure, is changed so that it interacts with the adjacent Ser137 (Pedersen et 
al., 2002). Ser137 corresponds to Ser138 in the mouse sulfotransferase structure and it 
forms a hydrogen bond with the 3’phosphate of PAPS. When the sulfonate moiety is 
cleaved from PAPS, the conformation of the lysine is changed so that it can form an ionic 
bond with the 5’phosphate, thus stabilizing the transition state of the reaction (Kakuta et 
al., 1998). On the other hand, it has been postulated that in SULT1A1, Glu83 and Asp134 
are important for activity and binding of PAPS (Chen et al., 2000), but this is not evident 
from crystal structures of the other isoforms. 
Human sulfotransferases are generally present as dimers in solution. They are capable 
of forming both homodimers and heterodimers (Kiehlbauch et al., 1995). A conserved 
dimerization motif of cytosolic sulfotransferases (KxxxTVxxxE) forms a zipper-like 
structure between the two monomers of SULT and it is located near the C-terminus 
(Petrotchenko et al., 2001). The monomers sit antiparallel with respect to each other and 
they are bound together by complementary hydrophobic interactions and backbone 
hydrogen bonds. In addition, lysine and glutamate form ion pairs at each end of the motif. 
X-ray structures and site-directed mutagenesis of mouse estrogen sulfotransferase have 
revealed that His108 functions as a catalytic base in the reaction and Lys106 is involved in 
the binding of estradiol (Kakuta et al., 1998). The histidine is conserved throughout the 
cytosolic sulfotransferase family. However, it is still mostly unclear which amino acids 
define the substrate specificities of individual SULT isoforms. When the structure of 
human SULT2A1 was compared to that of mouse SULT1E1, it was found that the amino 
acid differences in their binding pockets increased gradually from the bottom to the 
opening (Pedersen et al., 2000). Residues from three loops form the majority of the 
substrate binding site in SULT2A1: Pro14-Ser20, Glu79-Ile82, and Asn136-Lys144. 
There is also a C-terminal loop, Tyr231-Gln244, that covers the binding pocket. In 
SULT1E1 Tyr81 was found to be important for its selectivity toward estradiol 
(Petrotchenko et al., 1999). Tyr81 and Phe142 form a gate that regulates the binding 
affinity of SULT1E1 for estradiol. 
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Figure 7. Stereo view of the binding of PAP and dopamine (DP) to SULT1A3 (Lu et al., 2005; 
Reprinted with permission from Elsevier). 
 In the SULT1A3 structure, phenylalanines 24, 81, and 142 together with Glu146 and 
His149 form the substrate binding site (Dajani et al., 1999b). For the most part, these are 
the same residues as those suggested by Lu et al. (2005; Fig. 7). Phe142 is highly 
conserved in cytosolic SULTs but all the other residues that are suggested to contribute to 
substrate binding are variable between SULT families. On the other hand, within the 
subfamilies they are more conserved. All the other residues, except Glu146, suggested to 
take part in substrate binding of SULT1A3 are identical to those of SULT1A1. Glu146 
was identified as the single amino acid that defines the selectivity of SULT1A3 toward 
dopamine and other catecholamines by ion pairing with their amino group (Dajani et al., 
1998).  
Substrate inhibition is a very common enzyme kinetic phenomenon for SULTs. 
Gamage et al. (2003) found that SULT1A1 accommodates two p-nitrophenol (pNP) 
molecules in the active site. They proposed that the substrate inhibition is due to binding 
of substrate to one of the binding sites for pNP and only the other binding site is 
catalytically active. The structural basis of the phenomenon was also studied by Lu et al. 
(2008), who found that two amino acids, Tyr238 and Met137, are critical for substrate 
inhibition in SULT2A1. They proposed that the substrate inhibition can occur from 
binding of the substrate in either orientation. 
Overall, the substrate binding pockets of SULTs are flexible and can adopt their 
structures to accommodate many kinds of substrates. This makes their substrate specificity 
broad and overlapping with other SULTs. However, some characteristic substrates for 
most isoforms have been found and they are listed in Table 5. For instance, SULT1A1 
sulfonates p-NP even at very low substrate concentrations, and SULT1A3 is selective for 
catecholamines, although they are 93% identical in their amino acid sequences. SULT4A1 
is the isoform discovered most recently and it is expressed only in the brain. No substrate 
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has been found for this isoform and it seems that it is not capable of binding PAPS either 
(Allali-Hassani et al., 2007). However, it binds some other compounds such as adrenaline 
and thyroid hormones, suggesting that it may contribute to their homeostasis in brain by 
some other mechanism than sulfonation. 
Table 5. Some typical substrates for human SULTs 
SULT Characteristic substrates References 
1A1 p-Nitrophenol, p-nitrocatechol, p- 
cresol, 1-naphthol and other phenols,  
17-ethinyl-estradiol, 3,3’-diiodo- 
thyronine 
Falany, 1997; Veronese et al., 1994;  
Kester et al., 1999; Brix et al., 1999 
1A2 p-Nitrophenol 
Ethanol 
Raftogianis et al., 1999 
Schneider and Glatt, 2004 
1A3 Dopamine, tyramine, dopa Veronese et al., 1994; Falany, 1997;  
Sakakibara et al., 1998a; Brix et al., 1999 
1B1 Thyroid hormones 
Ethanol 
Wang et al., 1998  
Schneider and Glatt, 2004 
1C2 Thyroid hormones Li et al., 2000 
1C4 Ethanol Schneider and Glatt, 2004 
1E1 Estradiol, estrone, 17-ethinyl-estradiol 
and other steroids 
Forbes-Bamforth and Coughtrie, 1994;  
Falany et al., 1995; Falany, 1997 
2A1 Dehydroepiandrosterone and other  
steroids 
Falany, 1997; Pedersen et al., 2000 
2B1 Dehydroepiandrosterone, 
hydroxysteroids, pregnenolone  
(2B1_v1), cholesterol (2B1_v2) 
Her et al., 1998; Fuda et al., 2002 
4A1 Not known Allali-Hassani et al., 2007 
2.2.6 The dopamine sulfonating isoform SULT1A3 
SULT1A3 is the major isoform responsible for dopamine sulfonation in humans and it is 
encoded by two genes: SULT1A3 and SULT1A4 (Hildebrandt et al., 2004). 
Sulfotransferase corresponding to human SULT1A3 is not expressed in rodents 
(Eisenhofer et al., 1999; Honma et al., 2001) and that is probably the reason why 
glucuronidation is a more important metabolic pathway for dopamine in rat than in human 
(Wang et al., 1983). At least one non-synonymous coding single-nucleotide 
polymorphism has been found in SULT1A3 or SULT1A4 which leads to decreased levels 
of enzyme activity and protein levels in recombinant transient expression models (Thomae 
et al., 2003). 
Previously, SULT1A3 was called thermolabile phenolsulfotransferase (TL-PST) or 
monoamine-preferring PST (M-PST) to distinguish it from another phenolsulfotransferase, 
SULT1A1, previously called thermostable PST (TS-PST) or phenol-preferring PST (P-
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PST). Glu146 is an important amino acid residue determining the substrate specificity of 
SULT1A3 for catecholamines (Dajani et al., 1998). According to X–ray crystallographic 
studies, SULT1A3 is the only SULT having a carboxylate side chain in the active site 
capable of forming an ion pair with the protonated amino ethyl side chain of dopamine or 
other catecholamines (Dajani et al., 1998; 1999b; Bidwell et al., 1999; Lu et al., 2005). 
Dopa and tyrosine are also good substrates for SULT1A3 although they both have a 
negatively charged carboxyl group next to the amino group (Sakakibara et al., 1998a). 
The crystal structure of SULT1A3 was resolved in complex with PAP (Dajani et al., 
1999b), with lithium sulfate (Bidwell et al., 1999), and with PAP and dopamine (Lu et al., 
2005). In the latter structure (Fig. 7), the 3-hydroxy group of dopamine is aligned to form 
hydrogen bonds with residues His108 and Lys106 within the active site, whereas the 4-
hydroxy group cannot easily form these bonds (Lu et al., 2005). Only the 3-hydroxy group 
is also in line with the sulfate group of PAPS. In some studies, dopamine has been 
modeled in the active site so that the 4-OH is pointing to the catalytic His108 (Dajani et 
al., 1999b; Brix et al., 1999). It has been suggested that dopamine fits into the active site 
in such a way that it enables the sulfonation of either hydroxyl group because the flexible 
loops around the active site may undergo conformational change upon ligand binding 
(Bidwell et al., 1999; Dajani et al., 1999b; Barnett et al., 2004). However, these findings 
have not been supported by an enzyme kinetic analysis of dopamine sulfonation in vitro 
because the most widely used assays measure only the sum of the 3-O- and 4-O-sulfates 
and are unable to resolve the two isomers (e.g. Foldes and Meek, 1973). One of the aims 
of this study was to characterize the regioselective enzyme kinetics of dopamine 
sulfonation by SULT1A3. 
2.3 Enzyme kinetic equations 
Enzyme kinetics is a discipline that focuses on the reaction rates of enzymatically 
catalyzed chemical reactions. In this section, the enzyme kinetic equations used in this 
study are briefly introduced. Originally, these enzyme kinetic equations were developed 
for single-substrate reactions, but they apply to two-substrate reactions as well, provided 
that the concentration of one substrate is kept at a constant saturating level while 
determining the enzyme kinetic parameters for the other. 
The Michaelis-Menten equation, published in 1913, is the most commonly-used 
enzyme kinetic equation (Eq. 1 in Table 6.). In a usual enzyme-catalyzed reaction, the 
substrate is first bound to the enzyme. Then it is transformed into a product and released, 
or it is released back without transformation (Fig. 8A). The Michaelis-Menten constant 
(Km) describes the substrate concentration at which the reaction velocity is half of the 
Vmax, the limiting (or maximal) rate of the enzymatic reaction (Fig. 8B). The Km is 
associated with the affinity of the enzyme for the given substrate but it does not directly 
define the affinity. Vmax is mathematically the asymptote of the hyperbola that the 
Michaelis-Menten equation defines and the reaction velocity will never reach it at a finite 
substrate concentration (Cornish-Bowden, 1995). 
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Figure 8. The reaction scheme of a generalized enzyme-catalyzed reaction (A) and the curve 
defined by the Michaelis-Menten equation (B). E, S, and P represent the enzyme, 
substrate, and product, respectively.  
If enzyme is purified and quantified, one can determine the kcat value, i.e. turnover 
number, of the enzyme (Cornish-Bowden, 1995; Copeland, 2000). The units of kcat are 
reciprocal time and the value defines the maximal velocity at which an enzymatic reaction 
can proceed at infinite substrate concentration. It describes the velocity of multiple 
chemical steps that occur inside the enzyme after substrate binding, in other words, it tells 
how many substrate molecules the enzyme is able to transform into product molecules in a 
unit of time. Unlike UGTs, sulfotransferases are relatively easy to purify since they are 
cytosolic and not membrane bound proteins and hence the kcat can be measured for them. 
When the actual amount of active enzyme is not known, the kcat value can not be 
determined but one has to settle for determination of Vmax. Vmax values are reported in units 
of molecules of metabolite produced per incubation time units per amount of protein 
added to the reaction mixture (including proteins other than the enzyme studied). These 
values cannot be compared between different enzymes or enzyme preparations unless the 
expression levels of the enzymes in the preparations are somehow determined and the Vmax 
values are normalized to those levels. 
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Table 6. The enzyme kinetic equations used in this study. 
  
Name 
 
No.             
 
Equation 
 
Definitions 
Publi-
cations 
Michaelis-
Menten 
(1) [ ][ ]SK
SV
v
m +
×
=
max
 
S is the substrate concentration 
v is the reaction velocity 
Vmax is the limiting rate of the 
enzymatic reaction 
Km is the Michaelis-Menten 
constant 
Km = (k-1 + k2)/k1 (Fig. 8A) 
I-IV 
Substrate 
inhibition 
(2) [ ][ ] [ ]( )iS KSSK
SV
v
++
×
=
1
max
 
Ks is the substrate 
concentration at 0.5 ×Vmax 
Ki is the dissociation constant 
of the inhibitory SES complex 
(Fig. 9A) 
II,III 
Substrate 
inhibition 
(two sites) 
(3) [ ] [ ]( )[ ] [ ]2332
1
SKSKK
SKSV
v
++
+×
=
∞
 
V = k2[E]total 
K1 = k1Ks1s2/k2 
K2 = 1/(1/Ks1 + 1/Ks2) 
K3 = Ks1Ks1s2(1/Ks1 + 1/Ks2) 
(Fig. 10) 
I 
Biphasic 
kinetics 
(4) [ ][ ]
[ ]
[ ]SK
SV
SK
SV
v
mm +
×
+
+
×
=
2
2max
1
1max
 
 IV 
Hill (5) [ ][ ]nnA
n
SK
SV
v
+
×
=
max
 
KA is the substrate 
concentration at 0.5 ×Vmax 
n is the Hill coefficient 
II,III,IV 
Competi-
tive 
inhibition 
(6) [ ][ ] [ ]SKIK
SV
v
im ++
×
= )/1(
max
 
I is the inhibitor concentration  
Ki is the inhibition constant 
II 
 
Substrate inhibition (Eq. 2) is common in the enzyme kinetic studies of UGTs (e.g. 
Luukkanen et al., 2005) and SULTs in vitro but it is not normally seen at physiological 
concentrations of the substrates (Cleland, 1983). In a simple single-substrate reaction, 
another substrate molecule binds to the ES complex and inhibits its function (Fig. 9A). 
Prior to the formation of an inactive SES complex, an ES complex must be formed, thus 
substrate inhibition usually occurs only at high substrate concentrations (Copeland, 2000). 
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At infinite substrate concentration, the reaction rate approaches zero (Fig. 9B) rather than 
the Vmax. The Vmax in the substrate inhibition equation describes the theoretical maximal 
rate of the reaction without substrate inhibition. 
Figure 9. The reaction scheme for substrate inhibition (A) and the curve defined by the 
substrate inhibition equation (B). E, S, and P represent the enzyme, substrate, and 
product, respectively.  
Sulfotransferases sometimes exhibit exceptional substrate inhibition kinetics, as 
described by Gamage et al. (2003; Eq. 3). SULT1A1 has been crystallized with PAP and 
two p-nitrophenol (pNP) molecules in the active site and this has been proposed to explain 
the substrate inhibition. Gamage et al. (2003) also studied the substrate inhibition with 
enzyme kinetic methods. They suggested that the enzyme can bind pNP at site 1 (the 
active site) or site 2 (an additional binding site) and that occupancy of site 1 does not 
affect the binding of pNP at site 2, although pNP cannot be bound to site 1 if site 2 is 
occupied (Fig. 10A). The product pNP-sulfate cannot be released if site 2 is occupied but 
occupancy of site 2 does not completely abolish the catalytic activity of site 1. At a high 
substrate concentration both sites are occupied but still some residual activity is observed, 
and the reaction rate does not approach zero with infinite substrate concentration as it does 
in the case of ordinary substrate inhibition. The major disadvantage of this model is that 
the constants obtained from equation 3 cannot be intuitively interpreted. The K values are 
combinations of different rate constants (Table 6 and Fig. 10A) and the V is the only 
constant that is easily interpreted. It defines the limiting reaction velocity at infinite 
substrate concentration (Fig. 10B). A similar substrate inhibition pattern has been found 
for SULT1E1 (Zhang et al., 1998). The equation used to fit the data was different in that 
study but the resulting plot was similar to that presented in Figure 10B. 
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Figure 10. The two sites model of substrate inhibition kinetics (A) and the curve defined by the 
equation of Gamage et al. (2003) (B).  Site 1 is productive whereas Site 2 is 
unproductive. Binding of substrate at Site 2 prevents another substrate molecule from 
binding to Site 1. Binding to Site 1 does not affect the binding to Site 2. E, S, and P 
symbolize the enzyme, substrate, and product, respectively. The V defines the 
limiting reaction velocity at infinite substrate concentration 
Figure 11. The curve defined by the Hill equation. 
A biphasic equation is used to describe enzyme kinetics when there are multiple 
enzymes in the reaction mixture acting on the same substrate or one enzyme having 
multiple binding sites with different affinities and reaction rates. The resulting kinetic 
curve is a sum of two or more Michaelis-Menten curves (Eq. 4). This kind of kinetics has 
been seen e.g. with UGT2A isoforms (Sneitz et al., 2009).  
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The Hill equation (Hill, 1910; Eq. 5) describes cooperative binding or autoactivation. 
The curve defined by the Hill equation is sigmoidal (Fig. 11) and the Hill coefficient (n) 
describes the degree of sigmoidicity (Eq. 5). If the binding sites are similar to each other 
(e.g. in homo-oligomeric enzymes) and connected so that they affect eachother’s affinity 
for the substrate, they are said to exhibit cooperativity. With UGTs, sigmoidal curves are 
often produced (e.g. Soars et al., 2003). 
Figure 12. The reaction scheme of the reversible competitive inhibition of an enzymatic reaction 
(A). E, S, I, and P represent the enzyme, substrate, inhibitor, and product, 
respectively. The curves are defined by the Michaelis-Menten equation in the absence 
and presence of a competitive inhibitor (B). The highest curve has been obtained 
without an inhibitor and the others have been obtained in the presence of three 
different concentrations of the inhibitor. The lowest curve has been obtained with the 
highest inhibitor concentration. 
Competitive inhibition is a mode of enzyme inhibition where two compounds, the 
substrate and the inhibitor, compete for the same form of the enzyme (Fig. 12). The 
enzyme molecules that bind an inhibitor instead of the substrate are temporarily 
unavailable to the substrate, but those enzyme molecules that bind substrate instead of the 
inhibitor have the same reaction rate as they would have in the absence of the inhibitor. 
When the substrate concentration is high compared to the inhibitor concentration the 
observed reaction rate is similar to the maximum velocity of the reaction without the 
inhibitor. Thus, the Vmax is not affected by a competitive inhibitor. Instead, the inhibitor 
increases the substrate concentration that is needed to reach the half-maximal velocity and 
hence the apparent Km. 
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3 Aims of the study 
The aim of the study in publication I was to determine the regioselectivity of dopamine 
sulfonation by SULT1A3. Regioselectivity arose as an issue from molecular modeling 
studies with this enzyme at the Division of Pharmaceutical Chemistry when it was not 
obvious in which orientation the dopamine molecule should be placed in the model. The 
sulfonation kinetics of dopamine was determined using purified recombinant SULT1A3 
and the samples were analyzed by HPLC. Another aim of the study was to develop a rapid 
analytical method to separate the regioisomers of dopamine sulfate. 
After the first study, the focus was shifted from SULTs to UGTs. The aim of the study 
in publication II was to assess regio- and stereoselectivity of all known human UGT 
isoforms and 3 rat isoforms using β-estradiol and its diastereoisomer epiestradiol as 
substrates. Interspecies differences were also examined with human, rat, rabbit, pig, 
bovine, and moose liver microsomes. 
Publication III aimed to find out which UGT isoforms are responsible for dopamine 
glucuronidation in humans. Regioselectivity of the reaction was also of interest. After 
finding that UGT1A10 was the only UGT capable of dopamine glucuronidation at a 
significant level, twelve mutants of UGT1A10 were studied in order to determine the role 
of the amino acid residues at positions 90 and 93 in dopamine glucuronidation. To find out 
if the mutations affect the affinity as well as the activity, four of the mutants were also 
subjected to enzyme kinetic studies. 
During the course of studies II and III, it became obvious that UGT1A10 is a very 
highly active isoform in glucuronidation of estradiol and dopamine. In contrast, UGT1A9, 
which is very similar to UGT1A10 at the amino acid level, was less active and had 
opposite regio- and stereoselectivity. The aim of publication IV was to find out which 
amino acids determine the substrate specificity differences between UGT1A9 and 
UGT1A10 by examining chimeras and point-mutated enzymes that had parts from both 
isoforms. 
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4 Materials and Methods 
4.1 Chemicals 
Commercial chemicals and materials used in this study are listed in Table 7. Structures of 
the substrates are shown in Figure 13. Substrates used in this study were of the highest 
quality available (at least 98% purity). Dopamine sulfates (I) and dopamine-4-O-
glucuronide (II) were not commercially available and they were synthesized in our 
laboratory and used as standards. Synthesis of the dopamine-4-O-glucuronide was carried 
out as described by Uutela et al. (2009). Synthesis of the dopamine sulfates was based on 
previously published methods (Jain et al., 1986; Strobel et al., 1988) and the details are 
found in publication I. 
 
 
Figure 13. Chemical structures of the substrates used in this study. The conjugation sites that 
were examined are marked with arrows.  
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Table 7. Chemicals used in the study. 
 
Chemical 
 
Supplier 
 
Use 
Publi-
cation 
Acetic acid Mallinckrodt Baker, Deventer,  
Holland 
HPLC IV 
Acetonitrile  Rathburn Chemicals, Walkerburn,  
UK 
HPLC III, IV
Acryl amide  Flowgen, UK SDS-PAGE I 
Ammonium acetate Riedel-de Haën, Seelze, Germany HPLC IV 
Ammonium persulfate  Bio-Rad Laboratories, Hercules,  
CA 
SDS-PAGE I 
Ammonium sulfate WVR International, UK Enzyme purification I 
Ampicillin sodium salt Sigma-Aldricha Enzyme purification I 
Barium acetate WVR International, UK Activity assay I 
Ba(OH)2 Sigma-Aldricha Activity assay I 
Bradford reagent Sigma-Aldricha Protein assay I 
Brij 58 WVR International, UK Enzyme purification I 
Bovine serum albumin Perbio Science, UK Standard I 
Dimethylsulfoxide Riedel-de Haën, Seelze, Germany Activity assay II-IV 
Dipotassium hydrogen 
orthophosphate, anhydr. 
WVR International, UK Activity assay I 
Disodium hydrogen 
phosphate 
Fluka, Germany Activity assay I-IV 
Dobutamine 
hydrochloride 
Eli Lilly & Co., Indianapolis, IN Substrate IV 
Dopamine hydrochloride Sigma-Aldricha Substrate I, III 
Dulton VII Sigma-Aldricha SDS-PAGE I 
Emulsifier Safe PerkinElmer Life and Analytical  
Sciences, Boston, MA 
Activity assay I 
17α-Estradiol Sigma-Aldricha Substrate II, IV 
17β-Estradiol Sigma-Aldricha Substrate II, IV 
17β-Estradiol-β-D-
glucuronides, sodium salt 
Sigma-Aldricha Standard II 
Formic acid 98-100% Riedel-deHaën, Seelze, Germany HPLC III 
Glycine WVR International, UK SDS-PAGE I 
Hydrochloric acid 31.5- 
33% 
WVR International, UK SDS-PAGE I 
Idranal® III  Riedel-de Haën, Seelze, Germany HPLC I 
Isopropyl β-D- 
Thiogalactopyranoside 
Sigma-Aldricha Enzyme purification I 
Laemmli Sample Buffer Sigma-Aldricha SDS-PAGE I 
Luria Agar Gibco BRL Life technologies, UK Enzyme purification I 
Luria Broth base Invitrogen life technologies, UK Enzyme purification I 
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Table 7.   Continued. 
 
aSigma-Aldrich, St. Louis, MO or Steinheim, Germany 
 
 
 
Chemical 
 
Supplier 
 
Use 
Publi-
cation 
MgCl2 Merck, Darmstadt, Germany Activity assay II-IV 
MgSO4 WVR International, UK Enzyme purification I 
β-Mercapto-ethanol WVR International, UK Enzyme purification I 
Methanol  J.T. Baker, Deventer, Holland Activity assay 
HPLC 
I 
II, IV 
1-Naphthol Sigma-Aldricha Substrate IV 
1-Naphthyl glucuronide, 
sodium salt 
Sigma-Aldricha Standard IV 
PAPS Dr. H. Glatt, German Institute for  
Human Nutrition, Postdam, 
Germany 
Co-substrate I 
PAP[35S] PerkinElmer Life and Analytical  
Sciences, Boston, MA 
Co-substrate I 
Perchloric acid 70-72 % Merck, Darmstadt, Germany Activity assay II-IV 
Potassium dihydrogen  
orthophosphate 
WVR International, UK Activity assay I 
R-Propranolol Sigma-Aldricha Substrate IV 
S-Propranolol Sigma-Aldricha Substrate IV 
D-Saccharic acid 1,4- 
lactone 
Sigma-Aldricha Activity assay II, III 
Scopoletin Sigma-Aldricha Substrate II 
Sodium dihydrogen  
phosphate dihydrate 
Fluka, Germany Activity assay, 
HPLC 
I, II, 
IV 
Sodium dodecyl  
sulphate 
WVR International, UK SDS-PAGE I 
Tetramethylethylene-
diamine  
National diagnostics, UK SDS-PAGE I 
Tris(hydroxymethyl)-
methylamine 
WVR International, UK SDS-PAGE, 
Enzyme purification 
I 
UDP-glucuronic acid Sigma-Aldricha Co-substrate II-IV 
[14C]UDP-glucuronic 
acid 
PerkinElmer Life and Analytical  
Sciences, Boston, MA 
Co-substrate II-IV 
Water (Milli-Q Plus) Millipore, Molsheim, France HPLC I-IV 
ZnSO4  Sigma-Aldricha Activity assay I 
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4.2 Enzyme sources 
4.2.1 Expression and purification of SULT1A3 (I) 
The human SULT1A3 cDNA was expressed in E. coli and the protein was purified as 
described previously (Dajani et al., 1998; 1999a). Briefly, the SULT1A3 was purified 
from the E. coli cell-free extract by ammonium sulfate precipitation and two steps of 
chromatographic separation. First, the protein was applied to a HiTrap Q HP column 
(Amersham Biosciences) and thereafter to a 3’,5’-adenosine diphosphate agarose affinity 
column. The fractions were collected and tested using SDS-PAGE and a dopamine 
sulfonation assay namely the barium precipitation method of Foldes and Meek (1973). 
The most active and pure protein fractions were pooled and dialyzed overnight between 
the purification steps and desalted using a PD-10 column (Amersham Biosciences) at the 
end of the procedure. The final composition of the buffer used to store the protein was 50 
mM Tris/HCl buffer (pH 8) with 1 mM 2-mercaptoethanol. The protein concentration was 
estimated using bovine serum albumin as the standard (Bradford, 1976). 
4.2.2 Microsomal and recombinant UGTs (II, III, IV) 
The enzyme sources obtained commercially or according to previously published methods 
are listed in Table 8. For publication II, the cDNA of rat UGT2B3 was isolated by reverse 
transcription polymerase chain reaction from total liver RNA of Wistar rat. The sense 
primer upstream to the first ATG included an Xba1 site and the antisense primer 
downstream from the stop codon contained an Sph1 site. The amplified full-length DNA 
was subcloned as an Xba1-Sph1 fragment into the pUC118 vector and sequenced in both 
directions. The cDNAs for the 3 rat UGTs were transferred to the modified shuttle vector 
pFBXHA following insertion of a Sal1 restriction site just upstream of the original stop 
codon by PCR. Thereafter virus preparation and protein production were performed as 
previously described (Kurkela et al., 2003).  
In publication III, the activity of UGT2B10 toward dopamine was studied using 
freshly harvested cells because of possible partial inactivation upon membrane/microsome 
preparation (Kaivosaari et al., 2007). 
Mutated recombinant UGTs 1A9 and 1A10 (910-mutants for publication IV) were 
produced in our laboratory as His-tagged proteins in baculovirus-infected insect cells 
(Kurkela et al., 2003; Kuuranne et al., 2003). Mutagenesis was done by polymerase chain 
reaction, and the correctness of the resulting mutants was confirmed by DNA sequencing 
of the entire fragment that had been amplified by polymerase chain reaction and subcloned 
into the previously sequenced vectors. The constructed chimeric and point mutants were 
expressed in baculovirus-infected insect cells as described previously (Kurkela et al., 
2003; Kuuranne et al., 2003). Protein concentrations were determined by the BCA method 
(Pierce Biotechnology Inc., Rockford, IL). The relative expression levels of the 
recombinant UGTs were determined using a monoclonal antibody, tetra-His (QIAGEN, 
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Hilden, Germany), directed to the C-terminal His-tag that they carry, as described in detail 
previously (Kurkela et al., 2007).  
Table 8. Enzyme sources used in the study. 
Enzyme source Supplier or reference Publi-
cation 
New Zealand rabbit liver 
microsomes  
In Vitro Technologies, Baltimore, MD II 
Pooled human liver microsomes  BD Gentest, Woburn, MA II, III 
Pooled human intestinal microsomes BD Gentest, Woburn, MA II, III 
Recombinant human UGT2B15 BD Gentest, Woburn, MA II, III 
Rat liver microsomes Luukkanen et al., 1997 II 
Pig, bovine and moose liver 
microsomes 
Luukkanen et al., 1997 II 
Recombinant human UGTs 1A1, 
1A3-1A10, 2B4, 2B7, 2B10, 2B11,  
2B15, 2B17, and 2B28 
Kurkela et al., 2003; 2007; Kuuranne et al., 
2003 
II, III, 
IV 
Recombinant human UGTs 2A1-3 Sneitz et al., 2009 II, III 
rat UGTs 2B1 and 2B2 Kurkela et al., 2003; Mackenzie et al.,  
1984; Mackenzie, 1986a; 1986b 
II 
1A10F90 and 1A10F93 mutants Xiong et al., 2006; Starlard-Davenport et  
al., 2007 
III 
4.3 Enzyme assays 
In enzyme kinetic studies, the initial rate of the enzyme-catalyzed reaction should be 
measured (Allison and Purich, 1983). The initial rate period is shorter for low substrate 
concentrations and longer for high substrate concentrations because the relative substrate 
concentration changes faster at low concentration. The linear period ends approximately 
when more than 10% of the substrate is consumed. (There is no true linear range, but the 
curve is virtually straight.) Enzyme stability is another factor influencing the duration of 
the initial rate period. The initial rate period can be estimated by continuous assays, e.g. 
following the reaction by spectrophotometer or coupling the reaction to another (Cornish-
Bowden, 1995) or by assaying separate samples. In this study, preliminary tests were 
always conducted prior to enzyme kinetic studies in order to determine the linear range of 
the reaction with respect to incubation time and protein concentration.  
When determining enzyme kinetic parameters, the substrate concentration range 
should be at least from 0.2 to 5 times Km (Cornish-Bowden, 1995; Allison and Purich, 
1983). To estimate this range, preliminary studies were usually conducted prior to the 
selection of concentration levels. In estradiol glucuronidation assays it was not always 
possible to use as wide a concentration range as recommended, because of the solubility 
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problems encountered with concentrations above 300 µM. In dopamine glucuronidation 
studies, dopamine concentrations as high as 10 mM were used, but that was only 3 to 4 
times Km in most cases. 
Dimethyl sulphoxide (DMSO) was used in glucuronidation assays to enhance the 
solubility of the substrates. Of the substrates studied here, estradiols were especially 
poorly soluble in water, and a 5% DMSO concentration was used in the assays. Dehal et 
al. (2002) have shown in a poster that 5% DMSO did not inhibit the formation of 
estradiol-3-O-glucuronide by recombinant UGT1A1 or human liver microsomes. 
Uchaipichat et al. (2004) have investigated the effects of organic solvents on activities of 
recombinant UGTs in cell lysates of a human embryonic kidney cell line (HEK293). They 
concluded that some isoforms are more affected than others. UGT2B17 was especially 
sensitive to solvents. Kuuranne et al. (2003) noticed that DMSO was a better solvent for 
studying steroid glucuronidation than methanol or ethanol, and they used DMSO 
concentrations as high as 10%. Also, Dehal et al. (2002) have shown that DMSO is the 
least inhibitory solvent in UGT assays, although the effect is dependent on the isoform and 
the substrate. For SULTs, on the contrary, ethanol was recommended as a preferred 
solvent by Ma et al. (2003), but in the dopamine sulfonation study (I) no organic solvent 
was used. 
4.3.1 SULT assays (I) 
Dopamine sulfonation assays were carried out in 10 mM sodium phosphate buffer, pH 6.8, 
in a final volume of 160 µl, and the reactions were started with the addition of the enzyme. 
The reaction mixtures contained 0.5-1000 µM dopamine (12 different concentrations) and 
10 µM PAPS and they were incubated at 37°C for 10 minutes. All samples were assayed 
in duplicate and the reactions were stopped with 160 µl of chilled methanol. Control 
samples were incubated in the absence of dopamine, PAPS or enzyme to verify that no 
peaks eluted in HPLC chromatograms at the same time as dopamine sulfates. To some 
control samples, the enzyme was added after the addition of methanol to verify that the 
enzyme was properly deactivated under these conditions. The reaction mixtures were then 
frozen at –70°C and lyophilized. The dried samples were dissolved in 50 µl of HPLC 
mobile phase and centrifuged for 5 min at 16,100g, after which 20 µl of supernatant was 
injected into the HPLC system. Four sets of samples were made and analyzed on different 
days. 
4.3.2 UGT assays (II-IV) 
The detailed descriptions of the assay conditions for activity screening and enzyme kinetic 
studies can be found in the original publications II-IV. All incubations were done at 37°C 
and pH 7.4, mimicking physiological conditions. All samples contained 50 mM phosphate 
buffer and 5 mM MgCl2. The reactions were terminated by adding chilled 4 M perchloric 
acid (10% v/v of the total volume of the sample) and cooling the tubes in a cold block, 
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followed by centrifugation at 16,100g to remove the precipitated proteins. Screening 
assays were incubated in duplicate or triplicate and all enzyme kinetic samples were 
incubated in triplicate. Other conditions are summarized in Table 9. 
In glucuronidation studies, saccharolactone was traditionally added to reaction 
mixtures as an inhibitor of endogenous β-glucuronidase that might be present in enzyme 
preparations. However, in 2008, it was shown by Oleson and Court that saccharolactone 
was not needed for optimal activity. On the contrary, saccharolactone slightly inhibited 
some glucuronidation reactions (Oleson and Court, 2008). Consequently, although 
saccharolactone was used in studies II and III, it was omitted from the samples of the last 
publication (IV). 
Table 9. Incubation conditions in glucuronidation assays. 
Substrate 
 
S 
(µM) 
Enzyme Protein 
(mg/ml) 
Time 
(min) 
UDPGA 
(mM) 
DMSO 
(%) 
SLd 
(mM) 
II        
β-Estradiol, 
Epiestradiola 
1-100 19 human and 3 rat  
recombinant UGTs 
0.04-
0.2 
30 1 5 5  
β-Estradiol, 
Epiestradiola 
 
100 HIM, HLM, rabbit,  
pig, elk, bovine and   
rat liver microsomes 
0.4-3 60 1 5 5 
β-Estradiol, 
Epiestradiolb 
 
0.5-300 1A1, 1A3, 1A4, 1A7,  
1A8, 1A10, 2A1, 2A2, 
2B4, 2B7, 2B15,  
2B17, r2B1, r2B3  
0.008-
0.2 
10-45 1 5 5 
Scopoletinc 
(β-Estradiol) 
5-500 
(5-20) 
1A9  0.04 15 1 4 5 
III        
Dopaminea 
 
1000 
(or 
5000) 
HLM, HIM, 19 human 
recombinant UGTs,  
F90 and F93 mutants 
0.4-1.6 60 1 2 5 
Dopamineb 
 
100- 
10 000 
1A10, F90 and F93 
mutants, HLM, HIM 
0.1-0.4 30-45 1 and 5 2 5 
IV        
β-Estradiol, 
Epiestradiola 
100 1A9, 1A10, 
910 mutants 
0.5-4 60 2 5 - 
R- and S- 
Propranolola 
500 1A9, 1A10, 
910 mutants 
0.5-4 60 2 2 - 
Dobutaminea 1000 1A9, 1A10, 
910 mutants 
0.5-4 60 2 2 - 
1-Naphtholb 0.1-250 1A9, 1A10, 
910 mutants 
0.05-
0.5 
10-30 2 2 - 
aScreening assays; bEnzyme kinetic assays; cInhibition of UGT1A9 by β-estradiol; 
dSaccharolactone 
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4.4 Liquid chromatography 
HPLC was used to analyze the samples. The methods and equipment are listed in Table 
10. The flow rate was 1 ml/min with two exceptions. In publication III, the flow rate was 
0.9 ml/min and in publication IV, the flow was 1 ml/min up to 9.5 min and 2 ml/min from 
10 to 19.5 min when estradiol-glucuronides were analyzed. 
The methods for glucuronidation studies were validated by determining the linearity, 
quantitation limit and repeatability of the retention times when applicable. Screening 
assays in publication IV were done without quantitation and hence no standard curves or 
quantitation limits were determined. When authentic glucuronide standards were not 
available, radioactive glucuronides were produced by incubation and used as standards. 
More details can be found in the original publications II-IV. The method for the dopamine 
sulfonation assay was systematically validated and the validation data are presented under 
Results and Discussion. 
4.5 Enzyme kinetic analyses 
The enzyme kinetic parameters were determined by fitting the observed values of the 
reaction rates to different enzyme kinetic equations (Table 6) by a non-linear least squares 
regression method using SigmaPlot 9.0 with Enzyme Kinetics 1.1 (SPSS, Chicago, IL, 
US) in publication I or GraphPad Prism version 4.03 or 5 for Windows (GraphPad 
Software Inc., San Diego, CA) in publications II-IV. The best kinetic model was selected 
by considering the randomness of the residuals, the standard errors of the estimates, and 
the correlation coefficients. 
4.6 Molecular modeling (IV) and mRNA quantitation (III) 
A homology model for human UGT1A9 was constructed using Modeler 9v6 with a 
standard modeling scheme (Sali and Blundell, 1993). For the C-terminal domain, the 
human UGT2B7 was used as a template and for the N-terminal domain, UGT72B1 from 
Arabidopsis thaliana, GtfB from Mycolatopsis orientalis, and macrolide 
glycosyltransferase from Streptomyces antibioticus were used. The modeling of the 
segments of poor homology was aided by secondary structure predictions from 
PredictProtein (Rost et al., 2004). Full details of the model construction are described 
elsewhere (Laakkonen and Finel, 2010). Eventually, 1-naphthol was docked manually to 
this resultant model of UGT1A9. 
UGT1A9 and UGT1A10 mRNA quantitation in human tissues was done in the 
collabotarory laboratory as described in publication III. 
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Table 10. HPLC methods and equipment used in the study. 
Compounds RT (min) Mobile phase Column Detector 
Dobutamine 
glucuronides  
(IV)a 
meta: 17.9 
para: 14.9 
A: 20 mM ammonium  
acetate (pH 4.5) and  
B: methanol 
0-5 min: 10% B,  
5-25 min: 10-35% B, 
25-30 min: 35%  B, 
30-31 min: 35-10% B 
Hypersil BDS-
C18 
(250×4 mm 
5µm) 
Fluorescence detectora 
Wavelengths:  
Ex 285nm, em 313nm 
Dopamine-
glucuronides 
(III)a 
 
meta: 5.3 
para: 4.7 
A: 0.1 % aqueous formic 
acid and B: acetonitrile: 
0-1 min: 5% B, 
1-11 min: 5-20% B, 
11-13 min: 5% B 
Discovery® 
HS F5  
(4×150mm) 
(Bellafonte, 
PA) 
API3000 triple- 
quadrupole mass- 
spectrometerb with a 
turbo ion spray source 
Dopamine-
sulfates 
(I)c 
meta: 2.65 
para: 2.44 
25 mM phosphate buffer  
(pH 3.0) and 0.1 mM  
EDTA in water 
Synergi  
Polar-RPd 
(75×4.6 mm) 
Electrochemicale 
Electrode potentials:  
200 mV and 400 mV  
Estradiol-
glucuronides 
(II)c 
β3: 2.2 
β17: 3.0 
Epi3: 2.4 
Epi17: 4.2 
50% 25 mM phosphate  
buffer (pH 3.0) and  
50% methanol 
Chromolith 
SpeedRodf 
Fluorescence detectorc
Wavelengths:  
Ex 216nm, em 316nm 
Estradiol-
glucuronides 
(II)a 
  55% 25 mM phosphate  
buffer (pH 3.0) and  
45% methanol 
Chromolith 
SpeedRod 
Radioactivity detector 
(Reeve Analytical,  
Glasgow, U.K) 
Estradiol-
glucuronides 
(IV)a 
β3: 4.8 
Epi3: 5.7 
60% 25 mM phosphate  
buffer (pH 3.0) and  
40% methanol 
Chromolith 
SpeedRod 
Fluorescence detectora 
Wavelengths:  
Ex 216nm, em 316nm 
1-Naphthyl-
glucuronide 
(IV)a 
4.2 58% 50 mM phosphate  
buffer (pH 3.0) and  
42% methanol 
Hypersil 
BDS-C18 
(150×4.6mm 5 
µm) 
Fluorescence detectora 
Wavelengths:  
Ex 285nm, em 335nm 
Propranolol-
glucuronides 
(IV)a 
R: 5.5  
S: 31.2 
 
A: 50 mM  phosphate  
buffer (pH 3.0) and 
B: methanol 
R-propra: 55%A/45%B  
S-propra: 70%A/30%B 
Zorbax 
Eclipse Plus  
C18 
(150×4.6mm 
5 µm)g 
Fluorescence detectora 
Wavelengths:  
Ex 230nm, em 342nm 
Scopoletin-
glucuronide 
(II)a 
 4.6 90% 50 mM phosphate  
buffer (pH 3.0) and  
10% methanol 
Chromolith 
SpeedRod 
Fluorescence detectora 
Wavelengths:  
Ex 335nm, em 455nm 
 
aAnalyzed by Agilent 1100 HPLC, Agilent Technologies, Waldbronn, Germany; bApplied 
Biosystems/MDS Sciex, Concord, Canada; cAnalyzed by Shimadzu HPLC, Kyoto, Japan; 
dPhenomenex; eCoulochem II® Multi-Electrode Detector with Model 5011A Analytical Cell, ESA 
Biosciences, MA, US; fChromolith SpeedRod RP18e (50×4.6 mm) Merck, Darmstadt, Germany; 
gAgilent Technologies, Waldbronn, Germany 
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5 Results and Discussion 
The main results of the study are presented and discussed in this chapter. More details are 
found in the original publications I-IV. In addition, some unpublished results are presented 
here. 
5.1 Validation of the HPLC method for analysis of dopamine 
sulfates (I) 
The aim of publication I was to study regioselective sulfonation of dopamine by 
SULT1A3. A new analytical HPLC method was developed and validated by determining 
resolution, the limit of quantitation, linearity and the repeatability of retention times and 
peak areas (Table 11). The resolution (1.15) between the regioisomers was sufficient for 
accurate and reproducible separation of dopamine sulfates. Separation of dopamine-4-O-
sulfate, dopamine-3-O-sulfate, and dopamine was achieved within three minutes (Fig. 14).  
Table 11. Validation parameters for the HPLC method. 
 Dopamine-3-O-sulfate Dopamine-4-O-sulfate 
Retention time 2.65 min 2.44 min 
RSD of retention time 
      Within a day 
      Between days 
 
0.37% 
2.15% 
 
0.24% 
2.02% 
RSD of peak area  
(including sample preparation) 
5.55% 14.6% 
Linearity (R2) 0.997 0.994 
Limit of quantitation 33 nM 33 nM 
 
The analytical method developed here has many advantages over previous methods. 
One widely-used method for sulfotransferase activity studies is that developed by Foldes 
and Meek (1973), which is based on the use of the radioactive co-substrate PAPS. The 
radioactivity is transferred to the acceptor substrate during incubation and after that the 
unreacted PAPS is precipitated with barium hydroxide and zinc sulfate. After 
centrifugation, the resulting supernatant is mixed with scintillation fluid and the 
radioactivity is measured by a scintillation counter. The advantage of this method is that it 
is fast and it can be used for different substrates. However, one of the disadvantages is the 
poor repeatability of the precipitation as it depends e.g. on the temperature of the 
laboratory and the purity of the precipitation reagents. Also, the recovery of the products 
varies depending on the substrate and the precipitation conditions (Toth et al., 1987). In 
addition, if the substrate can be sulfonated at more than one position, like dopamine, the 
resulting regioisomers cannot be separated and quantitated with this method. The new 
HPLC method was developed to solve these problems. 
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Figure 14. The separation of dopamine sulfates by HPLC with electrochemical detection. A is 
dopamine-4-O-sulfate and B is dopamine-3-O-sulfate.The sample was incubated in 
the presence of the lowest dopamine concentration used, 0.5 µM. 
The new HPLC method is relatively fast for a conventional HPLC and much faster 
than previous methods (Elchisak and Carlson, 1982; Elchisak, 1983; Swann and Elchisak, 
1986; Toth et al., 1987; Kienzl and Eichinger, 1988). The fast separation of sulfates was 
achieved using a Synergi Polar-RP ether-linked phenyl column (75 mm × 4.6 mm, 
Phenomenex) that allows the use of an aqueous mobile phase without any organic solvent. 
It provides enhanced selectivity for polar and aromatic compounds and is therefore 
optimal for the separation of dopamine sulfates. Dopamine sulfates are not easily 
separated by ordinary reverse phase columns, and ion pairing agents have often been used 
in previous methods (Elchisak and Carlson, 1982; Elchisak, 1983; Swann and Elchisak, 
1986; Kienzl and Eichinger, 1988). Disadvantages of these methods include a longer 
equilibration time for the system, longer retention times for analytes and shorter life-times 
for the columns.  
In summary, the HPLC method developed here provides a fast, reliable and easy 
method for the separation and analysis of the regioisomers of dopamine sulfate and the use 
of electrochemical detection provides high selectivity and sensitivity.  
5.2 Conjugation of dopamine by SULT and UGT 
5.2.1 Sulfonation by SULT1A3 (I) 
Enzyme kinetics and regioselectivity of dopamine sulfonation by SULT1A3 was studied 
and the samples were analyzed by the newly developed HPLC method. The reaction was 
regioselective: the Vmax and Clint were, respectively, 7.5 and 6.4 times higher for 
dopamine-3-O-sulfate than for dopamine-4-O-sulfate (Table 12). The Km, on the other 
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hand, was similar for both regioisomers. The reactions followed the Michaelis-Menten 
equation at dopamine concentrations below 60 µM (Fig 15). At higher concentrations the 
reaction rate decreased markedly as a result of substrate inhibition. 
Our results from the enzyme kinetic analysis are in accordance with previous 
observations that SULT1A3 has selectivity for the 3-O-sulfonation of l-dopa (Suiko et al., 
1998) and that dopamine-3-O-sulfate is the form predominantly found in human blood. 
The Km and Vmax values obtained are in good agreement with those published previously 
using the barium precipitation assay, which showed a Km of approximately 1 M and a 
Vmax of almost 200 nmol/min/mg, obviously representing the combined formation of 
dopamine-3-O-sulfate and dopamine-4-O-sulfate (Dajani et al., 1999a). 
As expected, between 35 and 85% substrate inhibition was observed at high dopamine 
concentrations. In the present study, variable substrate inhibition by dopamine was 
observed, and in some cases the data fitted well in the equation proposed by Gamage et al. 
(2003, Eq. 3 in Table 6) where the residual enzyme activity is taken into account. In other 
cases, however, the substrate inhibition seemed to behave differently, and the activity 
approached zero at high dopamine concentrations.  
 
Table 12. Enzyme kinetic parameters for dopamine sulfonation by SULT1A3 (n=4). 
 Dopamine-3-O-sulfate Dopamine-4-O-sulfate 
Km (M) 2.59 ± 1.06 2.21 ± 0.76 
Vmax (nmol/min/mg) 344 ± 139 45.4 ± 16.5 
Clint (Vmax/Km) (ml/min/mg) 134 ± 39 20.8 ± 6.2 
Substrate inhibition (%) 35–85 40–80 
Figure 15. The formation of dopamine-3-O-sulfate (A) and dopamine-4-O-sulfate (B) by 
SULT1A3. Four sample sets were analyzed on different days and the sets are marked 
with different symbols. The samples were incubated in duplicate and the mean values 
are shown. 
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The variation in enzyme kinetic parameters was high between days (Table 12; Fig. 15). 
The reason for the different enzyme kinetics observed is not clear, but one explanation 
might be that the enzyme was not stable during processing and storage. Instability is more 
common with purified enzymes than microsomes, because the other proteins and lipids, 
that often protect enzymes, are not present (Allison and Purich, 1983). Also, adsorption to 
container walls and high dilution into the assay mixture may have caused problems. Ma et 
al. (2003) have recommended that incubations with expressed enzyme contain >12 g/ml 
total protein, especially when organic solvents are used in the reaction mixture. The 
SULT1A3 assays contained only 0.16 µg/ml protein per sample but, then again, no 
organic solvent was used. Some enzymes require the addition of reducing agents, e.g. 2-
mercaptoethanol or dithiothreitol, to the assay mixture in order to restore their activity. 
Reducing agents reduce critical thiol groups and prevent their cross-linking. Previously, it 
has been observed that oxidation and reduction affect the function of SULTs in vitro 
(Zhang et al., 1998; Marshall et al., 2000). In this study, the SULT1A3 enzyme was in the 
reduced form because 2-mercaptoethanol was present in the enzyme storage buffer, so the 
variation in the enzyme kinetics could not be due to different redox stages of the enzyme. 
In summary, despite the high variation in enzyme kinetic parameters between days, the 
results presented here show clearly that SULT1A3 strongly favors the 3-hydroxy group of 
dopamine over the 4-hydroxy group and may indeed be primarily responsible for the 
difference between the circulating levels of the regioisomers of dopamine sulfate in human 
blood. 
5.2.2 Glucuronidation by human UGTs (III) 
To find out which UGTs are responsible for glucuronidation of dopamine in human, 19 
human UGTs were expressed as recombinant proteins in insect cells and screened for 
dopamine glucuronidation activity. The main finding of this study was that UGT1A10 was 
the only isoform that glucuronidated dopamine at a significant rate. Very low activity was 
detected with UGTs 1A1, 1A3, 1A6, 1A7, 1A8, 1A9, 2A1, 2A3, 2B7, 2B11, 2B15, and 
2B17, but, for example, the normalized activity of UGT1A6, the second-best UGT after 
UGT1A10, was less than 1.3% of the activity of UGT1A10. 
The enzyme kinetic studies showed that the glucuronidation of dopamine by 
UGT1A10 followed slightly sigmoidal kinetics (Fig. 16) and the data were fitted to the 
Hill equation (Eq. 5 in Table 6). Dopamine glucuronidation by UGT1A10 was not 
regioselective and the KA and Vmax values were similar for both hydroxyls (Table 13). 
Human intestinal microsomes (HIM) exhibited similar enzyme kinetics to those of 
recombinant UGT1A10: the reactions exhibited slightly sigmoidal kinetics and the KA 
values were of the same order of magnitude (Fig. 16, Table 13). Human liver microsomes 
(HLM) glucuronidated dopamine at such a low rate and affinity that the enzyme kinetic 
parameters for the reaction could not be determined. The outcome of the studies with the 
human liver and intestinal microsomes, for its part, shows that the assumption that 
UGT1A10 is the only UGT that catalyses the reaction at a significant rate is correct, 
because the expression of UGT1A10 in the intestine is much higher than its expression in 
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the liver (III; Mojarrabi and Mackenzie, 1998; Cheng et al., 1999). The slight difference 
between the KA values of HIM and recombinant UGT1A10 may be explained by the fatty 
acids that are presumably more abundant in intestinal microsomes than in the membrane 
preparations of the insect cells. At least UGT1A9 and UGT2B7 are inhibited by fatty acids 
(Rowland et al., 2008), but to date it is not known whether fatty acids inhibit UGT1A10 or 
not.  
Table 13. The enzyme kinetic parameters for dopamine glucuronidation by UGT1A10 and 
human intestinal microsomes. 
 Dopamine-3-O-glucuronide Dopamine-4-O-glucuronide 
 KA  
(µM) 
Vmax  
(pmol/min/mg) 
n KA  
(µM) 
Vmax  
(pmol/min/mg) 
n 
UGT1A10 1950 ± 171 116 ± 4.89   1.52   2190 ± 205  140 ± 6.50   1.49 
HIM 2870 ± 267   25.3 ± 1.13 1.26 3410 ± 398 28.1 ± 1.56 1.17 
Figure 16. Glucuronidation of dopamine by UGT1A10 (A) and human intestinal microsomes (B). 
The samples were incubated in triplicate and the mean values are shown with SEM.     
 Dopamine-3-O-glucuronide;  Dopamine-4-O-glucuronide  
UGT1A7, UGT1A8, and UGT1A9 are the isoforms that are the most homologous to 
UGT1A10. Although their activity was very low for the both hydroxyls of dopamine, 
these three UGTs strongly favored the 3-OH over the 4-OH, unlike UGT1A10. The 
regioselectivities of these UGTs in the case of dopamine were in agreement with previous 
findings for the two catecholic hydroxyls of dobutamine (Alonen et al., 2005). It is 
interesting to note that there are only 16 amino acid residues in UGT1A10 that differ from 
the residues at the corresponding positions in UGT1A7, UGT1A8, or UGT1A9 (Fig. 4). 
Hence, during the later work for publication IV, dopamine was used in preliminary studies 
in an attempt to find the amino acids that are responsible for the differences in substrate 
selectivity between UGT1A9 and UGT1A10. Dopamine was also used to study the 
significance of phenylalanines 90 and 93 in UGT1A10 (III).  
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In conclusion, despite the low affinity, dopamine seems to be a useful probe substrate 
for UGT1A10, because it largely follows the two criteria for a good probe compound 
outlined by Court (2005): it is selective for one isoform and it exhibits similar affinity to 
the individual enzyme and to the microsomes from human intestine, where UGT1A10 is 
mainly expressed.  
5.2.3 Glucuronidation by rat UGTs 2B1, 2B2, and 2B3 (unpublished results) 
Dopamine glucuronide was recently found in rat brain (Uutela et al., 2009). In rat, the 
glucuronidation is a more important metabolic pathway for dopamine than in human 
(Wang et al., 1983), most likely because a sulfotransferase corresponding to human 
SULT1A3 does not exist in rodents (Eisenhofer et al., 1999; Honma et al., 2001). To date, 
it is not known which of the UGT isoforms are responsible for dopamine glucuronidation 
in rat. To begin, three rat UGTs, UGT2B1, UGT2B2, and UGT2B3, were expressed as 
recombinant proteins in insect cells and their activity toward dopamine was studied. The 
samples were incubated in duplicate for 60 minutes in the presence of 1 mM dopamine. 
The protein concentrations were 0.6-0.8 mg/ml. Under these conditions, UGT2B2 did not 
show any detectable activity, but the two other rat UGTs, UGT2B1 and UGT2B3, 
exhibited low activity toward dopamine (Fig. 17).  
Figure 17. Dopamine glucuronidation by three rat recombinant UGTs. The mean values for 
duplicate samples are shown. The samples were incubated in the presence of 1mM 
dopamine and UDPGA for 60 min. N.d. means that no activity was detected. 
Interestingly, in contrast to human UGT2Bs, the reaction was highly regioselective for 
the 4-OH of dopamine with both rat UGTs, especially with UGT2B1. This observation is 
in line with the previous study by Uutela et al. (2009), where dopamine-4-glucuronide was 
the major product in incubations with rat liver microsomes. Although UGT2B1, UGT2B2, 
and UGT2B3 are mainly expressed in the liver, low levels of mRNA were also found in 
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the rat brain (Shelby et al., 2003), thus they may contribute to the glucuronide formation 
there as well. In addition to these three, there are many other UGTs expressed in the rat 
brain, UGT1A1 being the most abundant (Shelby et al., 2003).  
In the future, it will be interesting to examine the dopamine glucuronidation activity of 
the other rat UGTs in order to find out which isoforms are mainly responsible for 
dopamine glucuronidation in different tissues in rat. Rat is one of the most important 
laboratory animals in drug development, which makes it especially relevant to study the 
differences between rat and human UGTs. 
5.3 The roles of phenylalanines 90 and 93 in dopamine 
glucuronidation by UGT1A10 
Recent studies have shown that two phenylalanine residues in UGT1A10, Phe90 and 
Phe93, may be directly involved in substrate binding (Xiong et al., 2006). The effect of 
mutating these Phe residues into Ala (Xiong et al., 2006; Miller et al., 2008) or Ala and 
Leu (Starlard-Davenport et al., 2007) on several enzymatic activities have been examined 
previously. The results were quite complex, revealing effects on either the Vmax or the Km, 
depending on the substrate. In this work, the effect on dopamine glucuronidation was 
studied. 
5.3.1 Activity screen of twelve F90 and F93 mutants (III and unpublished 
results) 
Phe90 and Phe93 residues were separately replaced by 6 residues of varying sizes and 
hydrophobicities. The smallest residue was glycine, followed by alanine, valine, leucine, 
isoleucine, and tyrosine. The 12 resulting mutants were expressed in baculovirus-infected 
insect cells and their activities toward dopamine were determined using one protein 
concentration and 5 mM dopamine. The activities were normalized for the relative 
expression levels of the mutants and the results were compared to control UGT1A10.  
The hypothesis was that Tyr would not affect the activity much because its structure is 
very similar to phenylalanine. They are both aromatic amino acids and their only 
difference is the phenolic hydroxyl found in tyrosine but not in phenylalanine. As 
expected, the most active mutant in this set was 1A10F93Y whose activity was 35 – 47% 
of wild-type UGT1A10 (Fig. 18). Less expectedly, 1A10F90Y turned out to be one of the 
least active enzymes in this study. All mutations lowered the activity toward both 
hydroxyls. In general, F90 mutations affected the normalized activity more than the F93 
mutations, but mutant F90L had higher activity than most of the F93 mutants (Fig. 18). 
Based on these results, it is not possible to tell whether the mutations affect the binding 
of dopamine to the active site. Enzyme kinetic studies were therefore conducted with four 
of the mutants. 
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Figure 18. The effect of the mutations in F90 and F93 on the glucuronidation activity of 
UGT1A10 toward dopamine. The results that have been published previously in 
publication III are marked with asterisks. The mean values of duplicate samples are 
shown. 
5.3.2 Enzyme kinetic studies of four F90 and F93 mutants (III) 
The enzyme kinetics of dopamine glucuronidation by four previously described 
UGT1A10 mutants, 10F90A, 10F90L, 10F93A, and 10F93L (Xiong et al., 2006; Starlard-
Davenport et al., 2007), were studied in order to find out if the lower activity observed in 
the screening assays was due to alterations in affinity or in the maximal reaction rate. 
Dopamine glucuronidation by UGT1A10 was best described by the Hill equation (Eq. 5 in 
Table 6) and the same type of sigmoidal kinetics was exhibited by the two mutants of 
phenylalanine 90, whereas mutants 10F93A and 10F93L exhibited Michaelis-Menten 
kinetics (Fig. 19). All the four mutations lowered the normalized Vmax of the reaction 
without significantly affecting Km or KA values. Substitution of either Phe90 or Phe93 
with alanine, as in 10F90A and 10F93A, lowered the activity toward the 4-OH of 
dopamine much more than replacement of either of these two phenylalanine residues with 
leucine. A possible explanation for this is that the latter mutations are more conservative 
when it comes to the hydrophobicity and size of the side chain. 
The two F to L mutants, 10F90L and 10F93L, differed sharply from each other with 
respect to dopamine glucuronidation at the 3-OH. The regioselectivity of the 10F90L 
mutant was similar to that of the wild type (i.e. no selectivity), whereas mutant 10F93L 
exhibited very different regioselectivity, glucuronidating dopamine at the 4-OH 
approximately 3 times faster than at the 3-OH.  
In conclusion, the results obtained in this study do not suggest that F90 or F93 are 
necessarily involved in direct interactions with dopamine in the active site of UGT1A10 
because the mutations did not affect the Km. There is an apparent disagreement between 
these results and those of previous studies that suggested that these phenylalanines are 
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located within the binding site of estrogens and other phenolic substrates (Xiong et al., 
2006; Starlard-Davenport et al., 2007). However, the explanation may be that the 
phenylalanines are located too far away from the catalytic His for the dopamine to reach 
when it sits in the active site. Unlike estrogens, dopamine is a small molecule with a 
flexible ethylamine side chain. 
Figure 19. Formation of dopamine-3-O-glucuronide (A) and dopamine-4-O-glucuronide (B) by 
UGT1A10 and its mutants 10F90A, 10F90L, 10F93A, and 10F93L. The reaction 
rates are normalized with respect to protein expression levels in each sample. 
5.4 Regio- and stereoselectivity in estradiol glucuronidation (II) 
In publication II, the regio- and stereoselectivities of human UGTs were studied using -
estradiol and epiestradiol as substrates. The focus of this work was mainly on structure-
activity relationships of the human UGTs, and these two substrates were selected for this 
study because both of them can be glucuronidated at two different positions, providing an 
interesting system for examining the substrate specificity of individual UGTs and the 
overlap between them in this respect. Moreover, the use of these two diastereoisomers 
could reveal how the configuration of the 17-OH affects its own glucuronidation by 
different UGTs, as well as its longer-range effects on the glucuronidation at the 3-OH of 
these compounds.  
5.4.1 Estradiol glucuronidation by human recombinant UGTs 
Initially, 19 human UGTs were screened for activity toward -estradiol and epiestradiol. 
The UGTs that exhibited undetectable or barely detectable activity under the conditions 
used in this study were UGT1A5, UGT1A6, UGT1A9, UGT2A3, UGT2B10, UGT2B11, 
and UGT2B28. Next, the UGTs that catalyzed the glucuronidation of at least one of the 
estradiol diastereoisomers were subjected to kinetic analyses. Detailed enzyme kinetic 
data are presented in original publication II. 
Dopamine-3-O-glucuronide
0 1000 2000 3000 4000 5000
0
20
40
60
80
100
Dopamine (µM)
Gl
uc
ur
on
id
at
io
n 
ra
te
(pm
ol/
m
in
/m
g)
Dopamine-4-O-glucuronide
0 1000 2000 3000 4000 5000
0
50
100
10F90A
10F90L
10F93A
10F93L
UGT1A10
Dopamine (µM)
Gl
uc
ur
on
id
at
io
n 
ra
te
(pm
ol/
m
in
/m
g)
A. B.
  
 
 
58
The general picture that emerges from this study is a distinct regioselectivity between 
the three subfamilies of the human UGTs. Regio- and stereoselectivity was more 
prominent in the UGT2B subfamily than in UGT1A or UGT2A subfamilies (Table 14). 
UGT1As were in general more active on 3-OH whereas UGT2Bs were mainly active on 
17-OH. The human UGTs of subfamily UGT2A that exhibited estradiol glucuronidation 
activity, UGT2A1 and UGT2A2, seem to have more promiscuous binding sites because 
they can glucuronidate these steroids at both positions. These patterns of estradiol 
glucuronidation by members of the different UGT subfamilies are not absolute, however, 
and the two exceptions to the rule were UGT1A4 and UGT2B15. Unlike most UGTs of 
the UGT1A family, UGT1A4 glucuronidated the two diastereoisomers solely at the 17-
OH position, but only at low rates. UGT2B15 was the only member of subfamily UGT2B 
that conjugated the two estradiols at the 3-OH rather than the 17-OH position (Table 14). 
The most active isoforms in this study were UGT1A10 and UGT2B7. They had 
completely opposite regioselectivity, as UGT1A10 was more active on 3-OH and 
UGT2B7 was only active on 17-OH of both enantiomers. The activity of UGT1A10 
toward epiestradiol was very high, as was its activity toward the 3-OH group of -
estradiol. In the latter case, a combination of low Ks and high Vmax value led to an 
exceptionally high Clint value. UGT2B7, in turn, revealed exceptionally high affinity for 
epiestradiol. 
Table 14. Regio- and stereoselectivity of human UGTs in estradiol glucuronidation. A minus 
sign means that glucuronide formation, if any, was below the detection limit, 
whereas each additional “+” indicates an approximate 10-fold increase in Clint . 
UGTs 1A5, 1A6, 1A9, 2A3, 2B10, 2B11, and 2B28 had very low or no activity with 
both substrates and were not included in the enzyme kinetic studies.  
UGT 
Epiestradiol- 
3-glucuronide 
β-Estradiol- 
3-glucuronide 
Epiestradiol- 
17-glucuronide 
β-Estradiol- 
17-glucuronide 
1A1 ++ ++ - - 
1A3 ++ + (+) + 
1A4 - - + + 
1A7 + - - - 
1A8 ++ + - (+) 
1A10 +++ ++++ - ++ 
2A1 ++ + + + 
2A2 + + + (+) 
2B4 - - ++ - 
2B7 - - ++++ +++ 
2B15 ++ (+) - - 
2B17 - - - ++ 
 
The rules of stereoselectivity among the different UGTs are even more complex than 
those of regioselectivity and may be viewed as a dimension of the substrate specificity. 
This is particularly striking in the case of the three human UGT2Bs that glucuronidated 
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either substrate at the 17-OH position. Hence, UGT2B4 is specific for the 17-OH of 
epiestradiol, UGT2B17 is strictly specific for -estradiol, and UGT2B7 exhibited a clear 
preference, but not strict specificity, for epiestradiol (Table 14).  
When only glucuronidation at the 17-OH position is considered, the results are in line 
with the results of Sten et al. (2009) on the glucuronidation of testosterone and 
epitestosterone. In these steroids, 17-OH is the only hydroxyl group (Fig. 20). Therefore, 
consistent with the results obtained with estradiols, UGT1As were not highly active on 
testosterone or epitestosterone. The stereoselectivities of all UGTs toward testosterones 
were similar to those towards estradiols. UGT2B17 even had very similar Km values for -
estradiol and testosterone. UGT2B7, on the other hand, had much lower activity for 
testosterone than for -estradiol and its Km for testosterone was not determined, but its Km 
values for both epiestradiol and epitestosterone were very low. Thus, it can be concluded 
that the Km values of UGT2B7 and UGT2B17 for these steroids are not affected by the 
configurations of the A and B rings. 
 
Figure 20. The structures of estradiol and testosterone diastereomers. 
In study II, UGT1A10 was the most active human enzyme in glucuronidation of -
estradiol and epiestradiol at the 3-OH position. The estradiol glucuronidation activity of 
UGT1A10 was reported to be low in a previous study (Lepine et al., 2004), perhaps 
because of the use of a low activity batch of recombinant UGT1A10. In another study 
(Cheng et al., 1999), estradiol was not included, but the activity of UGT1A10 toward 
many other substrates including estrogens was studied and found to be lower than the 
activity of UGT1A8. For example, activity toward propranolol or 1-naphthol was not 
detected. On the other hand, Strassburg et al. (1998a) reported that UGT1A10 had higher 
activity than UGT1A8 toward a range of substrates including -estradiol and 1-naphthol. 
Also, Basu et al. (2004) observed high activity toward various substrates including -
estradiol. Therefore, we took further steps to ensure that our findings were correct.  Both 
UGT1A8 and UGT1A10 were expressed in human embryonic kidney cells (HEK293) 
without any C-terminal fusion peptide as described previously (Uchaipichat et al., 2004) 
and their estradiol glucuronidation activities were examined in the collaboratory 
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laboratory. The results were broadly consistent with the results obtained with the “his-
tagged” UGTs expressed in the insect cells. In particular, the normalized Vmax value for 
UGT1A10 was 2 orders of magnitude higher than that of UGT1A8 (data not shown). 
Some studies have suggested that UGT1A10 activity depends on phosphorylation 
(Basu et al., 2004; 2005). Protein kinases that are involved in the phosphorylation may not 
be present or as active in insect cells as in human cells. However, this does not explain the 
differences in UGT1A10 activity toward -estradiol in this study and the previous study of 
Lepine et al. (2004), because insect cells were used in both studies. On the other hand, 
Dellinger et al. (2007) have suggested that in HEK293 cells, the majority of the 
UGT1A10 is not localized in the microsomal fraction, which is most often used in 
glucuronidation studies. That might explain the low activity observed by Cheng et al. 
(1999). Incubation conditions, such as pH and use of organic solvents or detergents, may 
also have a great impact on the results, but clearly further studies are required to fully 
elucidate the reasons behind the large variability in the activity of UGT1A10 found by 
different research groups around the world. 
There are large differences in estradiol glucuronidation activities between the human 
UGT1A7 through UGT1A10, despite the high degree of sequence similarity among them 
(Fig. 4). UGT1A10 was very active toward the 3-OH of epiestradiol and even more active 
toward the 3-OH of -estradiol (Table 14). UGT1A7 and UGT1A8 showed higher activity 
toward 3-OH of epiestradiol than that of -estradiol. In the case of UGT1A9, the activity 
toward the 3-OH of epiestradiol was barely detectable at 100 µM substrate concentration, 
but toward -estradiol, it was below the detection limit (data not shown).  
Taken together, our results show that many UGTs are capable of estradiol 
glucuronidation, but they catalyze these reactions with varying regioselectivities and 
stereoselectivities and differ in terms of catalytic efficiency. Hence, the assumption of 
broadly overlapping specificities of UGTs is not justified, particularly when dealing with 
compounds that may be glucuronidated at more than one position. 
5.4.2 Competitive inhibition of human UGT1A9 by β-estradiol 
To determine whether UGT1A9 binds either estradiol diastereomer, we examined the 
inhibition of scopoletin glucuronidation activity of UGT1A9 by the two estradiols. The 
results confirmed that -estradiol can substantially inhibit the activity of UGT1A9 as 
reported previously (Mano et al., 2004). In contrast, the inhibitory effect of epiestradiol on 
this activity was limited. 
To further clarify the mode of inhibition by -estradiol, the apparent Km values for 
scopoletin glucuronidation in the absence and presence of three concentrations of the 
inhibitor were determined. To determine what type of inhibitor -estradiol was toward 
UGT1A9, the method recommended by Copeland (2000) was used. Briefly, the 
untransformed data from incubations in the absence and presence of three concentrations 
of β-estradiol were fitted separately to the Michaelis-Menten equation, and the apparent 
Km and Vmax values for scopoletin were determined. These values were then substituted 
into the reciprocal transformation of the Michaelis-Menten equation and thus four straight 
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lines were obtained. In the case of competitive inhibition the intersection of these lines is 
located on the y-axis, as observed in this case (Fig. 6C in publication II). Other types of 
inhibition, noncompetitive and uncompetitive, would not produce a similar intersection, 
but in the case of noncompetitive inhibition the intersection would be on the left side of 
the y-axis, whereas in the case of uncompetitive inhibition the lines would not intersect at 
all. The Ki value for -estradiol was determined by fitting the untransformed data to Eq. 6 
(Table 6). The outcome of this experiment revealed that -estradiol is a competitive 
inhibitor of UGT1A9 with a Ki value of 5.8 ± 1.1 M, a very close value to the Ks of 
UGT1A10 for -estradiol. 
In summary, although UGT1A9 does not glucuronidate -estradiol or epiestradiol, it 
binds -estradiol with nearly the same affinity as UGT1A10. Hence, no activity does not 
always mean no binding. Because the dissimilarity between UGT1A9 and UGT1A10 was 
so obvious, -estradiol and epiestradiol were used as model substrates when the selectivity 
differences between these two UGTs were studied in more detail in the later publication 
(IV). 
5.4.3 Estradiol glucuronidation by human liver and intestinal microsomes 
The results obtained with recombinant human UGTs were further verified by incubations 
with human liver and intestinal microsomes. Of those UGTs that were active toward 
estradiol, UGT1A10 and UGT1A8 are expressed in the intestine but not (or at very low 
level) in the liver, whereas UGT1A1, UGT1A3, UGT1A4, and UGT2Bs are mainly 
expressed in the liver (Table 1), UGT2B4, UGT2B7, UGT2B10, and UGT2B15 being the 
most abundant isoforms (Izukawa et al., 2009; Ohno and Nakajin, 2009). Accordingly, β-
estradiol-3-glucuronide, the preferred product of UGT1A10, was also the main product in 
human intestinal microsomes (Fig. 21). Epiestradiol-17-glucuronide, mainly produced by 
UGT2B7 and UGT2B4, was the most abundant product in liver microsomes (Fig. 21). 
These results suggest that the recombinant proteins, which are expressed with an 
additional polyhistidine tail (His-tag), are good tools for predicting glucuronidation 
activities also in the native enzymes. 
 
Figure 21. Glucuronidation of estradiols by human liver and intestinal microsomes. 
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5.4.4 Interspecies differences in estradiol glucuronidation 
Interspecies differences in estradiol glucuronidation were studied with three recombinant 
rat UGTs and liver microsomes from various species. Glucuronidation of -estradiol and 
epiestradiol by three rat UGTs from the UGT2B subfamily, UGT2B1, UGT2B2, and 
UGT2B3, were studied. The results showed that UGT2B2 was not active toward either 
estradiol diastereomer, UGT2B1 only glucuronidated -estradiol, and UGT2B3 
glucuronidated both diastereomers but only at the 17-OH position (Table 15). The 
regioselectivity and stereoselectivity of UGT2B1 were similar to those of the human 
UGT2B17, with activity nearly restricted to the 17-OH of -estradiol. Interestingly, 
UGT2B3 was highly and similarly active toward the 17-OH of both diastereomers, a clear 
exception among all the tested UGTs.  
It is difficult to identify UGT2B orthologues across species, because most of the 
members in the mammalian UGT2B subfamily are at least 70% similar in sequence 
(Mackenzie et al., 1997; 2005). Based on the results with estradiols and dopamine, it can 
be concluded that the rat UGTs 2B1 and 2B3 are unique and different from human 
UGT2Bs at least when it comes to regio- and stereoselectivity toward these substrates. 
 
Table 15. Regio- and stereoselectivity of rat UGTs in estradiol glucuronidation. A minus 
sign means that glucuronide formation, if any, was below the detection limit, 
whereas each additional “+” indicates an approximate 10-fold increase in Clint. 
. 
In addition, liver microsomes from several different animal species were examined. 
Rat liver microsomes were from animals that had been treated with Aroclor 1254 (a 
mixture of polychlorinated biphenyls) in order to induce the expression of UGTs. UGTs 
1A1, 1A6, 1A7, 2B1, and 2B12 are more induced by polychlorinated biphenyls than the 
other UGTs in rat liver (Shelby and Klaassen, 2006). Both human and rat liver 
microsomes exhibited higher glucuronidation activity at the 17-OH position than at the 3-
OH position (Fig. 22). Rat liver microsomes exhibited a clear preference for -estradiol. 
However, the estradiol glucuronidation activity of microsomes from rabbit, pig, bovine, 
and moose was high, and glucuronidation occurred mainly at the 3-OH position. The 
results are in line with a previous report (Falany et al., 1983) where only the -estradiol 
glucuronidation activities of rat and rabbit liver microsomes were studied. To summarize, 
this study showed that the differences in glucuronidation between animal species are large 
and they should be taken into account when using animal models to predict drug 
metabolism in human. 
 
UGT 
Epiestradiol- 
3-glucuronide 
β-Estradiol- 
3-glucuronide 
Epiestradiol-17-
glucuronide 
β-Estradiol- 
17-glucuronide 
2B1 - (+) - +++ 
2B2 - - - - 
2B3 - - +++ +++ 
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Figure 22. Estradiol glucuronidation in human and animal liver microsomes. 
5.5 Key amino acid residues involved in functional differences 
between UGT1A9 and UGT1A10 (IV) 
The aim of publication IV was to find the location of the residues that play a central role in 
determining the activity differences between UGT1A9 and UGT1A10. The activities of 
the different UGT1A9-UGT1A10 (910) chimeras and other mutants, alongside the parent 
enzymes, were examined using compounds whose glucuronidation varied considerably 
between UGT1A9 and UGT1A10. R- and S-propranolol, -estradiol, epiestradiol, and 
dobutamine (Fig. 13) were selected for this large screen because earlier studies showed 
differences in their stereoselectivity or regioselectivity (II; Alonen et al., 2005; Sten et al., 
2006). Dopamine was used in preliminary studies but it was replaced by dobutamine 
because the latter was a better substrate for both UGTs studied. 1-Naphthol was chosen as 
a substrate for the enzyme kinetic studies because it is a substrate for both UGT1A9 and 
UGT1A10 and there is a relatively large difference between their Km values as well as two 
orders of magnitude difference in their Vmax values. 
In the beginning, a minimalist assumption was made that a single amino acid 
difference between UGT1A9 and UGT1A10 could lead to the activity differences between 
them. The chimera approach was adopted to eliminate most of the 33 differing residues in 
the first round of mutagenesis and then to focus on the central residues. Different 
mutations were designed to confer UGT1A10-like activity on UGT1A9, since it would 
have more evidential value than the opposite arrangement in which UGT1A10 would lose 
its properties as a result of mutation. Although this study focused on the residues that 
differ between UGT1A9 and UGT1A10, UGT1A7 and UGT1A8 were also taken into 
account when trying to locate the most important residues that affect the substrate 
selectivity.  
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Epiestradiol-3-glucuronide 14 21 96 85 98 65
ß-Estradiol-3-glucuronide 39 53 100 100 100 100
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ß-Estradiol-17-glucuronide 10 100 0 0.10 5.1 0.82
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5.5.1 UGT1A9-UGT1A10 chimeras 
The N-terminal domain encoded by exon 1 was divided into 5 parts and they were named 
A, B, C, D, and E (Table 16). Five single-segment chimeras were constructed. In these 
chimeras, each of the five N-terminal segments of UGT1A9 was separately replaced by 
the corresponding segment from UGT1A10. The chimeric mutants generated in this way 
were named 910 (combination of UGT1A9 and UGT1A10) and a letter (A–E), denoting 
the segment originating from UGT1A10.  
The activities of the chimeras toward estradiols, propranolols, and dobutamine were 
screened. None of the single-segment chimeras greatly resembled UGT1A10 in the 
activity studies (Table 17), strongly suggesting that the functional differences between 
UGT1A9 and UGT1A10 could not be explained by a single amino acid difference. The 
results implied that segments A and E and even segment D with 10 variable residues (Fig. 
4, Table 16) do not contribute significantly to the substrate selectivity differences between 
the two UGTs. 910B and 910C, on the other hand, showed qualitative changes in regio- 
and stereoselectivity patterns toward UGT1A10, but the reaction rates were only a fraction 
of that exhibited by UGT1A10 so the observation was inconclusive. 
Table 16. Mutations in segments A-E in UGT1A9-UGT1A10 chimeras. In segment B, the five 
point-mutations that were separately studied after the chimeras are shown in bold 
text. 
Segment Amino acids Mutations 
A 1-83 (C3R, T4A, and L10V in signal peptide), R42Q, G67E 
B 84-147 L86Q, D87N, K91M, A92V, V102A, R103Q, Y106F, G111S, 
Y113S, N114S, D115G, I116F, F117L, N123H, K129N, K131R 
C 148-181 N152T, A169T, L173F, Y176H 
D 182-235 R192N, I193D, R208W, M212V, E216D, L219F, H221Q, 
R222Y, F223L, K225R 
E 236-285 E241A 
 
Four double-segment chimeras were then constructed and their activities were 
analyzed. In these chimeras, two of the five segments of UGT1A9 were replaced by the 
corresponding segments from UGT1A10 and they were named 910AB, 910BC, 910CD, 
and 910BD. Construction of these double-segment chimeras was undertaken because it 
was reasoned that if the minimal number of crucial residues for the differences between 
UGT1A9 and UGT1A10 is two and if they are located within different segments, then a 
double-segment chimera may contain the correct combination and will yield a UGT1A10-
like activity. Segment E was not included in the double-segment chimeras because the 
single amino acid difference between UGT1A9 and UGT1A10 in that segment had no 
significant effect on the enzymatic activity. Of double-segment chimeras, 910BC and 
910BD were the most similar to UGT1A10 when considering regio- and stereoselectivity 
and the results were quite promising, although their activities were not nearly as high as 
that of UGT1A10 (Table 17).  
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Table 17. Regio- and stereoselectivity of UGT1A9, UGT1A10, and 910 chimeras. 
 
S-
Propranolol-
glucuronide 
R- 
Propranolol-
glucuronide 
- 
Estradiol-3-
glucuronide 
Epi-
estradiol-3-
glucuronide 
Dobutamine-
para-
glucuronide 
Dobutamine-
meta-
glucuronide 
 Peak area relative to protein concentration and UGT expression level* 
1A9 3300 470 10 76 69 440 
1A10 2000 8900 86000 18000 16000 5300 
910A 1300 190 - 31 26 190 
910B - 240 280 77 69 54 
910C - 170 480 190 510 1800 
910D 870 180 36 120 15 56 
910E 3000 480 51 81 51 480 
910AB - 88 73 - 36 28 
910BC 280 810 3600 1200 840 510 
910BD 460 1000 6500 280 300 110 
910CD 150 270 320 1300 89 460 
*The mean values of duplicate or triplicate samples are shown. 
- No detectable activity 
 
Table 18. Enzyme kinetic parameters for the glucuronidation of 1-naphthol by UGT1A9, 
UGT1A10, and the 910 chimeras. The Vmax values are normalized with respect to 
the relative expression level of the enzyme in each sample. 
Enzyme/Mutant 
and  
Kinetic Model   
Km1   Vmax1   Km2   Vmax2   
[S] 
Range 
M  pmol/min/mg  M  pmol/min/mg  M 
1A9B????  0.04 ± 0.01  12.5 ± 0.4  15.7 ± 3.9  17.4 ± 1.6  0.1-25 
1A10MM????  4.9 ± 0.2  1970 ± 35  - - 0.1–25 
910AB????  0.10 ± 0.02  13.0 ± 1.0  4.5 ± 3.2  4.8 ± 0.8  0.1-25 
910BMM????  6.3 ± 0.4 7.7 ± 0.1 - - 1–250 
910CMM????  1.0 ± 0.05  914 ± 10 - - 0.1–25 
910DMM????  11.8 ± 0.6  217 ± 5.4  - - 0.1–25 
910EB????  0.13 ± 0.02 10.9 ± 0.6  27.0 ± 12.3  19.6 ± 4.1 0.1-25 
910BCMM????  7.1 ± 0.4  131 ± 3.0 - - 0.1–25 
910BDMM????  7.1 ± 0.3 146 ± 1.8 - - 0.5–100 
910CDMM????  17.9 ± 1.0 1950 ± 36  - - 0.5–100 
MMMichaelis-Menten; BBiphasic 
 
Because the activity screenings were performed in the presence of a single 
concentration for each substrate and enzyme, enzyme kinetic studies were conducted to 
learn more about the substrate affinity and maximal turnover rate of each mutant. To keep 
the study a reasonable size, one substrate, 1-naphthol, was selected for these analyses. 
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The 1-naphthol glucuronidation analyses of the single- and double-segment chimeras 
revealed that the activity (low), affinity (high), and kinetic model (biphasic) of 910A and 
910E were similar to those of the parent UGT1A9 (Table 18). On the other hand, 910D 
and 910CD exhibited much higher Km values than UGT1A9, or even UGT1A10, whereas 
910C had intermediate Km and Vmax values. The highest 1-naphthol glucuronidation rate of 
the chimeras was observed with 910CD and the lowest with 910B. The Km most similar to 
that of UGT1A10 was observed with 910B, even though the Vmax was very low (Table 
18). In addition, two double-segment chimeras that contained segment B, 910BC and 
910BD, exhibited Km values close to that of UGT1A10, and their activity rates were 
higher than that of UGT1A9 (Table 18). The kinetic parameters for 910AB were not 
determined because of its very low activity toward 1-naphthol.  
In summary, the results obtained with chimeras showed that those in which segment B 
was replaced by that from UGT1A10 were the most similar to UGT1A10 when 
considering regio- and stereoselectivity together with affinity for 1-naphthol (Tables 17 
and 18). In addition, segment B includes the residues and regions that were previously 
reported to play a major role in substrate binding (Dubois et al., 1999; Lewis et al., 2007; 
Nishiyama et al., 2008); hence, it was subjected to further studies.  
5.5.2 Point mutations within residues 84-147 of UGT1A9 
Assuming that the most important residues are in segment B, five point mutations were 
made in that segment and their effects on the glucuronidation activity were studied. Within 
segment B there are 16 residues that differ between UGT1A9 and UGT1A10, but only 5 
of them are unique to UGT1A10 compared to UGT1A7, 1A8, and 1A9 (Fig. 4). We 
concentrated on these 5 unique residues, because UGT1A7 and UGT1A8 resembled 
UGT1A9 rather than UGT1A10 in dobutamine and dopamine glucuronidation (III; 
Alonen et al., 2005) and to a large extent also in stereoselectivity in estradiol 
glucuronidation (II). The point mutants were named 9D87N, 9V102A, 9R103Q, 9N114S, 
and 9F117L. 
Four of the mutations, namely D87N, V102A, R103Q, and N114S, did not change the 
regio- and stereoselectivity of UGT1A9 (Table 19). Their normalized activities were also 
very close to those of UGT1A9 with all three substrates and they did not affect either the 
affinity or the activity of UGT1A9 toward 1-naphthol (Table 20). The only substantial 
difference was in the Vmax1 of 9N114S, which was about twice that of UGT1A9.  
The effect of the F117L mutation varied between the substrates (Table 19 and 20). 
With dobutamine, the regioselectivity was changed toward that of UGT1A10 but the 
activity was very low. With propranolol, the ratio of the reaction rates was not inverted, 
although the glucuronidation rate of S-propranolol was reduced more than that of R-
propranolol when compared to rates with UGT1A9. With estradiol there was no change in 
stereoselectivity or activity. With 1-naphthol, on the other hand, 9F117L had a Km very 
close to that of UGT1A10 and its Vmax was also approximately ten times higher than that 
of UGT1A9. 
 
  
 
 
67
Table 19. Regio- and stereoselectivity of the point mutants and the triple mutant in segment 
B. 
 
S-
Propranolol-
glucuronide 
R-
Propranolol-
glucuronide 
- 
Estradiol-3-
glucuronide
Epi-
estradiol-3-
glucuronide 
Dobutamine-
para-
glucuronide 
Dobutamine-
meta-
glucuronide 
 Peak area relative to protein concentration and UGT expression level* 
1A9 3300 470 10 76 69 440 
1A10 2000 8900 86000 18000 16000 5300 
9D87N 6100 900 21 180 100 620 
9V102A 3200 530 15 89 160 520 
9R103Q 3500 450 11 75 62 470 
9N114S 2900 430 28 170 120 430 
9F117L 420 210 11 36 87 56 
910B(115-117) 18000 1100 100 280 1700 1700 
*The mean values of duplicate or triplicate samples are shown. 
 
Table 20. Enzyme kinetic parameters for the glucuronidation of 1-naphthol by UGT1A9, 
UGT1A10, the point mutants, and the triple mutant in segment B. 
Mutant and 
Kinetic Model  
Km1 or Ks Vmax1   Km2   Vmax2   Ki   
[S] 
Range 
M  pmol/min/mg  M  pmol/min/mg  M  M 
1A9B????  0.04 ± 0.01  12.5 ± 0.4  15.7 ± 3.9  17.4 ± 1.6  - 0.1-25 
1A10MM????  4.9 ± 0.2  1970 ± 35  - - - 0.1–25 
9D87NB????  0.09 ± 0.01  12.3 ± 0.3 41.9 ± 9.4  38.4 ± 5.1  - 0.1-25 
9V102AB???? 0.11 ± 0.01  8.7 ± 0.2 26.7 ± 3.4 24.8 ± 1.5 - 0.1-25 
9R103QB????  0.15 ± 0.01  14.8 ± 0.5 32.4 ± 16  16.9 ± 4.3  - 0.1-25 
9N114SB????  0.09 ± 0.02 25.5 ± 1.8 30.0 ± 3.2  11.5 ± 4.6  - 0.1-25 
9F117LSI????  3.4 ± 0.2  107 ± 4.0 - - 81.4 ± 14  0.1–25 
910B(115–117)SI?? 2.3 ± 0.2  436 ± 10 - - 167 ± 16 1–100 
BBiphasic; MMMichaelis-Menten; SISubstrate inhibition 
 
Finally, we made one more construct, 910B(115-117), with three mutated amino acids: 
D115G, I116F, and F117L. This mutant was more active than 9F117L with all substrates 
studied. Like 9F117L, it did not change the stereoselectivity with estradiol or propranolol 
but this mutant had different regioselectivity than UGT1A9 with dobutamine (Table 19). 
With dobutamine, the activity toward both catecholic hydroxyls was higher than that of 
UGT1A9 but the mutant did not show any preference for either one of them. With 1-
naphthol, 910B(115-117) showed even higher activity than 9F117L, although not as high as 
910C or UGT1A10, and the Km was close to that of UGT1A10. The effect of this triple 
mutant on the Km for 1-naphthol (Table 20) was probably due to the F117L mutation 
alone, suggesting that Asp115 and Ile116 of UGT1A9 do not directly interact with the 
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substrate. In the molecular model of UGT1As (Laakkonen and Finel, 2010), this segment 
is predicted to be helical, which prevents three consecutive residues from pointing in the 
same direction. 
Based on the results with the five point mutants and the triple-mutant, it was concluded 
that residue 117 in UGT1A9 and UGT1A10 affects the Km of 1-naphthol and may be in 
direct contact with the substrate when it is bound in the active site.  
5.5.3 Combinations of single-segment chimeras and point mutations 
Next, 6 single-segment chimeras with additional point mutations in another segment of the 
protein were constructed. In four of these mutants (910B-N152T, 910B-A169T, 910B-
L173F, and 910B-Y176H), segment B was similar to that of UGT1A10 and, additionally, 
one of the four dissimilar amino acids in segment C was mutated. Two other mutants 
(910C-F117L and 910D-F117L) had segment C or D from UGT1A10 in addition to the 
point mutation F117L in segment B. 
Concerning regio- and stereoselectivity of these mutants, 910B-L173F and 910B-
Y176H were similar to 910B and 910D-F117L was similar to 9F117L, suggesting that the 
mutations L173F and Y176H and segment D were not very important in substrate 
selectivity differences. Three other mutants, 910B-N152T, 910B-A169T, and 910C-
F117L, exhibited similar regio- and stereoselectivity to UGT1A10, and 910B-N152T had 
the highest activity among them (Table 21). 
All the six mutants had Km values for 1-naphthol that were similar to, or higher than, 
those of UGT1A10 and 910B. 910D-F117L had the highest Km of all the enzymes studied, 
and its Vmax was also rather high, reaching 50% of that of UGT1A10. 910B-L173F and 
910B-Y176H had very low activities, like 910B. 910B-A169T had somewhat higher 
activity but its Km was also higher. 910B-N152T had the highest activity of all the mutants 
that had part B from UGT1A10 and an affinity similar to those of 910B and UGT1A10. It 
may thus be suggested that the residue at position 152 faces the active site. This would be 
in agreement with the previous findings of Fujiwara et al. (2009). However, 910C-F117L 
was the most similar to UGT1A10 when considering both affinity and activity.  
Finally, assuming that both Phe117 and Asn152 in UGT1A9 affect substrate 
specificity and interact with the bound substrate, we prepared the double mutant 9F117L-
N152T hoping that this combination would largely confer UGT1A10-like activity on 
UGT1A9. However, the results were disappointing because the activity of this mutant was 
very low in the glucuronidation of propranolols, estradiols, and dobutamine. The affinity 
for 1-naphthol was also very low, even lower than that of UGT1A10, although the Vmax 
toward this substrate was high. 
In summary, residues between Leu86 and Tyr176 of UGT1A9 appear to determine the 
substrate selectivity differences between UGT1A9 and UGT1A10. Within this region, 
residues at positions 115, 116, 117, 152, and 169 seem to contribute to the catalytic 
properties that were studied here. The results indicate that interactions between several 
amino acids, rather than the presence of a single residue in a “strategic” location within the 
active site, govern the complex substrate selectivity of the UGTs. 
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Table 21. Regio- and stereoselectivity of the chimeras having an additional point mutation 
in another segment and the double mutant 9F117L-N152T. 
 
S- 
Propranolol-
glucuronide 
R- 
Propranolol-
glucuronide 
- 
Estradiol-3-
glucuronide 
Epi-
estradiol-3-
glucuronide 
Dobutamine-
para-
glucuronide 
Dobutamine-
meta-
glucuronide 
 Peak area relative to protein concentration and UGT expression level* 
1A9 3300 470 10 76 69 440 
1A10 2000 8900 86000 18000 16000 5300 
910B-N152T 1300 3000 2500 590 800 800 
910B-A169T 290 1900 880 72 160 100 
910B-L173F 19 31 110 22 57 52 
910B-Y176H 53 150 110 14 36 27 
910C-F117L 400 620 650 390 410 140 
910D-F117L 860 360 33 43 63 53 
9F117L-
N152T 720 500 96 28 110 140 
*The mean values of duplicate or triplicate samples are shown. 
 
Table 22. Enzyme kinetic parameters for the glucuronidation of 1-naphthol by UGT1A9, 
UGT1A10, the chimeras having an additional point mutation in another segment, 
and the double mutant 9F117L-N152T. 
Mutant and  
Kinetic Model   
Km(1) or Ks Vmax(1) Km2   Vmax2   Ki   
[S] 
Range 
M  pmol/min/mg  M  pmol/min/mg  M  M 
1A9B????  0.04 ± 0.01  12.5 ± 0.4  15.7 ± 3.9  17.4 ± 1.6  - 0.1-25 
1A10MM????  4.9 ± 0.2  1970 ± 35  - - - 0.1–25 
910B-N152TMM? 6.2 ± 0.4  112 ± 2.6 - - - 0.1–25 
910B-A169TSI???12.8 ± 1.3 67.7 ± 3.6  - - 240 ± 49 0.5–100 
910B-L173FSI??? 2.4 ± 0.2 1.8 ± 0.06  - - 287 ± 59 0.5–100 
910B-Y176HMM? 11.6 ± 0.5 6.6 ± 0.1 - - - 0.5–100 
910C-F117LMM??2.8 ± 0.1 1090 ± 17  - - - 0.1–25 
910D-F117LMM??121 ± 5.7  838 ± 19 - - - 1–250 
9F117L-N152TSI?20.8 ± 1.8 1320 ± 74 - - 111 ± 14 0.5–100 
BBiphasic; MMMichaelis-Menten; SISubstrate inhibition 
5.5.4 Molecular modeling of the active site of UGT1A9 
During the course of the experimental work described above, a homology model for 
selected human UGTs was constructed (Laakkonen and Finel, 2010). In addition to the 
conserved structural elements of the N-terminal domain, there are two long and highly 
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variable interstrand loops, which are predicted to fold into several short helices. These 
variable loops correspond closely to segments B and D, as defined in this study. In 
accordance with the experimental results, the model showed that segments A and E are the 
farthest away from the active site, without any direct contacts with the bound substrate 
except the catalytic His37 within segment A (Miley et al., 2007; Patana et al., 2008). 
His37 of either UGT1A9 or UGT1A10 is expected to face the substrate binding site of the 
enzyme and be crucial for activity but not for the selectivity differences between these 
enzymes. In contrast, the results with the 910-mutants suggested that Phe117 may be 
responsible for the high affinity of UGT1A9 for 1-naphthol.  
To test this hypothesis (and the model itself), 1-naphthol was docked between the side 
chain of His37 of UGT1A9 and the anomeric carbon of the glucuronic acid moiety of 
UDPGA. Because of the rigidity of the 1-naphthol structure and the presence of a single 
reactive group within this substrate, it may be assumed that it only possesses rotational 
freedom in the active site. Depending on the rotational orientation of the bound aglycone, 
segments B, C, and D come into close proximity with it. The two most extreme 
orientations for 1-naphthol point either to segments C and D (169–173 and 188–192) or to 
segment B (residues 116–119). In the latter position, the substrate comes in contact with 
Phe117, which is found close to the catalytic His and may stack with the aromatic ring of 
1-naphthol, in full agreement with the activity data. It is tempting to speculate that the 
biphasic kinetic model observed with UGT1A9 may originate from the different 
orientations of 1-naphthol in the active site, the high-affinity and the low-affinity 
orientations, and when the F117 is removed by mutation, the high affinity is lost.  
5.6 mRNA expression of UGT1A9 and UGT1A10 in human tissues 
(III) 
Because UGT1A10 seemed to be the most active UGT in dopamine and estradiol 
glucuronidation, the expression of this isoform in human tissues was evaluated. Although 
studies with some tissues were done previously, there were inconsistencies in the results, 
particularly regarding whether this enzyme is expressed in liver (Strassburg et al., 1997; 
1998a; 1999; Mojarrabi and Mackenzie, 1998; Cheng et al., 1999; Zheng et al., 2002; Li 
et al., 2007b; Nakamura et al., 2008). The expression pattern of UGT1A9 was also 
analyzed in the same tissues. The results confirm that UGT1A10 is expressed mainly in 
the intestine followed by adipose tissue, trachea and stomach, but very low mRNA levels 
were also found in the liver, testis, and prostate. UGT1A9, in contrast to UGT1A10, is 
expressed mainly in the liver and in the kidneys. UGT1A9 is also expressed to 
considerable levels in the small intestine, colon, and adipose tissue, and to low levels in 
adrenal gland, placenta, prostate, stomach, testis, trachea, and thyroid, but neither 
UGT1A9 nor UGT1A10 was detected in the brain, ovary, or uterus, which are target 
tissues of dopamine and -estradiol. 
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6 Summary and Conclusions 
During the course of the studies for this doctoral thesis, many important new findings 
were made that provide better understanding of the drug metabolizing enzymes and their 
substrate selectivity. First, a new HPLC-method was developed and used for dopamine 
sulfonation studies (I). This was the first time that regioselectivity of dopamine 
sulfonation by sulfotransferase (SULT) 1A3 was studied by enzyme kinetic analysis. 
Previously, it has been suggested that specificity of transport proteins or arylsulfatases 
might be the factors influencing the circulating levels of dopamine-3-O-sulfate and 
dopamine-4-O-sulfate in the blood (Strobel et al., 1990). The results presented here 
indicate that SULT1A3 strongly favors the 3-hydroxy group of dopamine over the 4-
hydroxy group and may indeed be primarily responsible for the difference in the 
circulating levels of dopamine sulfates in human blood (I). These results are fully 
consistent with the increasing amount of crystallographic and other data appearing on the 
mechanism of the sulfonation reaction. 
Glucuronidation of dopamine and estradiol by 19 human recombinant UDP-
glucuronosyltransferases (UGTs) was studied (II, III). The results highlight the importance 
of the human UGT1A10, which has sometimes been considered a low activity isoform 
(Cheng et al., 1999; Lepine et al., 2004). On the other hand, high activity toward various 
substrates has been observed by other groups (Strassburg et al., 1998a; Basu et al., 2004). 
The reason for the varying results is not clear, although some speculations have been 
presented e.g. phosphorylation and extra-microsomal localization of UGT1A10 (Dellinger 
et al., 2007; Basu et al., 2004; Basu et al., 2005). Further studies are required to fully 
elucidate the reasons behind the large variability observed in the activity of UGT1A10. 
However, our results with recombinant UGT1A10 were supported by the results obtained 
with microsomal preparations from human liver and intestine (II, III). 
Both SULT1A3 and UGT1A10 are expressed mainly in the intestine. Although the 
liver is usually considered to be the major metabolizing organ, the surface area of the 
intestinal mucosa is enormous. Therefore, these two intestinal enzymes may play 
important roles in the first step of inactivation and detoxification of drugs and other 
xenobiotics in vivo. Moreover, almost half of the endogenous dopamine is produced in the 
mesenteric organs, where most of the dopamine sulfates are produced (Eisenhofer et al., 
1997). In vivo, UGT1A10 is probably much less important in dopamine metabolism than 
SULT1A3, whose affinity to dopamine is approximately 1000 times higher (I, III). 
Despite the low affinity, dopamine was identified as a new possible probe substrate for 
UGT1A10 due to its selectivity, and it was used to study mutants of this enzyme (III). 
Phenylalanines 90 and 93 were replaced by six amino acids of different sizes. The results 
revealed distinct effects that are likely to be dependent on differences in the size of the 
side chain and in their positions within the protein. Four mutants were subjected to kinetic 
analyses and the amino acid changes were found to affect only the Vmax of the dopamine 
glucuronidation but not the Km, presumably reflecting the lack of direct contact of these 
residues with dopamine in the active site. Studies with more substrates are under way in 
our laboratory and the findings should facilitate better understanding of the substrate 
specificity of the human UGT1A10 and the factors that determine it. 
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Glucuronidation of -estradiol and epiestradiol was studied with respect to regio- and 
stereoselectivity of UGTs (II). In general, UGT1As were more active on the 3-OH than on 
the 17-OH of both diastereomers, whereas the regioselectivity of UGT2Bs was the 
reverse. The stereoselectivity of UGT2B7 and UGT2B17 toward the 17-OH of -estradiol 
and epiestradiol was similar to that toward testosterone and epitestosterone (Sten et al., 
2009). UGT2B7 and UGT1A10 were the most active enzymes in estradiol 
glucuronidation. UGT1A10 was more active on the 3-OH of -estradiol than on the same 
hydroxyl of epiestradiol. UGT1A9 glucuronidated only epiestradiol, and only to a barely 
detectable level, but it also bound -estradiol with an affinity similar to that of UGT1A10. 
In consequence, epiestradiol and -estradiol were used in the latter study of the differences 
between UGT1A9 and UGT1A10 (IV). 
The substrate selectivities of UGT1A9 and UGT1A10 partly overlap, but there is some 
dissimilarity in their regio- and stereoselectivities as well as in affinities and activities 
toward many substrates. In mature proteins, there are only 33 amino acids that differ 
between these two enzymes and modify their function in subtle ways. In study IV, seven 
amino acids were identified that were unimportant for the selectivity differences between 
UGT1A9 and UGT1A10: R42, G67, D87, V102, R103, N114, and E241. On the other 
hand, F117 was identified as an important residue in the binding of 1-naphthol. In 
addition, residues at positions 115, 116, 152, and 169 had significant impacts on the 
catalytic properties that were studied here, and the residues at position 152 and 169 
especially affected activity. Because there is no crystal structure of the N-terminal domain 
of any UGT, determination of the important amino acids is a difficult task. Previously, 
some membrane proteins have been studied with atomic force microscopy in situ (Engel 
and Gaub, 2008) and perhaps that would be a useful tool in determining the structures of 
UGTs in the future. 
In drug discovery, metabolism studies are part of the non-clinical phase. The 
glucuronidation studies with rat UGTs and liver microsomes from five species implied 
that animal models are not always reliable in predicting glucuronidation in humans. In 
addition, the studies with recombinant enzymes provide new information about the 
substrate selectivity of human UGTs and SULT1A3 that can even be of help in creating 
new predictive models for early ADME studies. 
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